On December 20, 2019, a putative class and derivative lawsuit captioned Jacobs v. Meghji, C.A. No. 2019-1022-MTZ (the “Action”) was filed in the Court of Chancery of the State of Delaware (the “Court”), challenging a series of equity commitment transactions that Infrastructure & Energy Alternatives Inc. (“IEA”) had entered into in 2019. The Action named IEA’s Board of Directors, Oaktree Power Opportunities Fund III Delaware, L.P., and Ares Management Corp. as Defendants, with IEA as a Nominal Defendant.
On July 28, 2021, the parties in the Action reached a tentative settlement, which provided that IEA would enter into a series of recapitalization transactions to improve its capital structure. On July 28 and August 2, 2021, those contemplated recapitalization transactions were consummated (the “2021 Transactions”).
During the pendency of the Action, the Supreme Court of the State of Delaware rendered its decision in the matter of Brookfield Asset Management, Inc., et al. v. Martin Rosson, et al., 261 A.3d 1251 (Del. 2021) (“Brookfield”), which the parties believe eliminated the viability of the class claims in the Action.
On July 25, 2022, IEA and MasTec Inc. (“MasTec”) announced that they entered into a definitive agreement under which MasTec would acquire all of the outstanding shares of IEA in a cash-and-stock transaction valued at $14.00 per IEA share (the “Merger”). On October 7, 2022, IEA and MasTec announced that they had completed the Merger, following approval by the IEA stockholders at a special meeting held on October 7, 2022.
As a result of the Merger, MasTec became IEA’s sole stockholder and, as a result, the parties to the Action agreed that (i) plaintiff no longer had standing to assert derivative claims on behalf of IEA, (ii) the tentative settlement reached on July 28, 2021 was void, and (iii) the Action should be dismissed as moot.
After the parties agreed that a mootness dismissal was required, the parties engaged former Vice Chancellor Joseph R. Slights of the Court of Chancery of Delaware as a mediator to address the question of the extent to which plaintiff’s counsel were entitled to attorneys’ fees and expenses for what they contended were corporate benefits that the 2021 Transactions provided to IEA. On March 8, 2023, the parties reached agreement upon IEA’s payment of attorneys’ fees and expenses of $5,000,000. The Court of Chancery has not been asked to review or approve, and will pass no judgment on, this payment.
In June 2023, the Court entered an order dismissing the Action with prejudice as to plaintiff, and without prejudice as to all other members of the putative class, and directed that this notice be distributed in the following forms: via a press release on a national wire service, a posting on plaintiff’s counsel’s website, and a posting on IEA’s website. After this notice has been distributed and the parties have attested to the fact to the Court, the dismissal will become final and the Court will no longer retain jurisdiction over the Action.
Levi & Korsinsky, LLP announces that a FATE class action lawsuit has been filed on behalf of investors who purchased Fate Therapeutics, Inc.(FATE) securities between April 2, 2020, and January 5, 2023. For more on the FATE Lawsuit please contact us today.
According to the Fate lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the global collaboration and option agreement for cell-based cancer immunotherapies that the Company entered into with Janssen Biotech, Inc. (the “Janssen Collaboration Agreement”) was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement’s on Fate’s long-term clinical and commercial profitability; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Fate you have until March 22, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an IBM class action lawsuit has been filed on behalf of investors who purchased International Business Machines Corporation (IBM) securities between January 18, 2018, and October 16, 2018 For more on the IBM Lawsuit please contact us today.
According to the IBM lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Strategic Imperatives Revenue growth, CAMSS (the distinct components of “Cloud,” “Analytics,” “Mobile,” “Security,” and “Social”) and CAMSS Components’ revenue growth, and the Company’s Segments’ revenue growth were artificially inflated as a result of the wrongful reclassification/misclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; and (ii) IBM was materially less successful in growing its Strategic Imperative business, reporting materially higher growth than it actually achieved only by wrongfully reclassifying and misclassifying revenue from non-strategic to strategic thereby reporting publicly materially false Strategic Imperative Revenue.
If you suffered a loss in IBM you have until March 14, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a YMAB class action lawsuit has been filed on behalf of investors who purchased Y-mAbs Therapeutics, Inc. (YMAB)This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020, through October 28, 2022, For more on the YMAB Lawsuit please contact us today.
According to the Y-mAbs lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Y-mAbs misrepresented the U.S. Food and Drug Administration’s (“FDA”) willingness to approve omburtamab, the Company’s lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA’s requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit March 31, 2022, Biologics License Application prior to reaching an agreement with the FDA on the content of the application.
If you suffered a loss in Y-mAbs you have until March 20, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a LUV class action lawsuit has been filed on behalf of investors who purchased Southwest Airlines Co. (LUV) securities between June 13, 2020, and December 31, 2022. For more on the LUV Lawsuit please contact us today.
According to the Southwest lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Southwest continuously downplayed or ignored the serious issues with the technology it used to schedule flights and crews and how the Company stood to be affected worse than other airlines in the event of inclement weather, and (2) the Company did not discuss how its unique point-to-point service and aggressive flight schedule could leave it prone in the event of inclement weather; and (3) as a result, defendants’ statements about Southwest’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Southwest you have until March 13, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ENVX class action lawsuit has been filed on behalf of investors who purchased Enovix Corporation (ENVX) This lawsuit is on behalf of all investors who purchased or otherwise acquired Enovix common stock (or Rodgers Silicon Valley Acquisition Corp. common stock prior to July 15, 2021) between February 22, 2021, and January 3, 2023, For more on the ENVX Lawsuit please contact us today.
According to the Enovix lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: Enovix overstated its ability to produce batteries at a commercial scale. Despite touting its “meaningful progress” in developing its manufacturing capabilities, Enovix continued to face serious production problems. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period.
If you suffered a loss in Enovix you have until March 7, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AVYA class action lawsuit has been filed on behalf of investors who purchased Avaya Holdings Corp.(AVYA) securities between November 22, 2021, and November 29, 2022. For more on the AVYA Lawsuit please contact us today.
According to the Avaya lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s internal control over financial reporting was deficient in several areas; (ii) as a result of these deficiencies, the Company had failed to design and maintain effective controls over its whistleblower policies and its ethics and compliance program; (iii) the Company’s deteriorating financial condition was likely to raise substantial doubt as to its ability to continue as a going concern; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Avaya you have until March 6, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a GOTU class action lawsuit has been filed on behalf of investors who purchased Gaotu Techedu Inc. F/K/A Gsx Techedu Inc. (GOTU) securities between March 5, 2021, and July 23, 2021, For more on the GOTU Lawsuit please contact us today.
According to the Gaotu lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) China was barring tutoring for profit in core school subjects, and this policy change would restrict foreign investment in a sector that had become essential to success in Chinese school exams; and (2) the impact such regulations would have on Gaotu’s operations and profitability and the value of Company securities.
If you suffered a loss in Gaotu you have until February 28, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a DAKT class action lawsuit has been filed on behalf of investors who purchased Daktronics, Inc. (DAKT) securities between March 10, 2022, and December 6, 2022 For more on the DAKT Lawsuit please contact us today.
According to the Daktronics lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing challenges that increased costs, including supply chain disruptions, that impacted Daktronics’ ability to fund inventory levels and operations; (2) as a result, it was probable that some portion of the Company’s deferred tax assets would not be realized; (3) as a result, Daktronics was reasonably likely to record a material valuation allowance to its deferred tax assets; (4) there were material weaknesses in the Company’s internal controls over financial reporting related to income taxes; (5) the foregoing presented liquidity concerns and there was substantial doubt as to the Company’s ability to continue as a going concern; and (6) as a result of the foregoing, defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Daktronics you have until February 21, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a GAIA class action lawsuit has been filed on behalf of investors who purchased Gaia, Inc. (GAIA) securities between December 26, 2017, and November 7, 2022 For more on the GAIA Lawsuit please contact us today.
According to the Gaia lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s Q1 2019 subscriber count was overstated; (2) the Company lacked adequate internal controls; (3) as a result, defendants had a heightened risk of regulatory scrutiny and ultimately being subject to an investigation and action by the United States Securities and Exchange Commission; and (4) as a result of the foregoing, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Gaia you have until February 21, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a SUNL class action lawsuit has been filed on behalf of investors who purchased Sunlight Financial Holdings Inc. f/k/a Spartan Acquisition Corp. II (SUNL) securities between January 25, 2021, and September 28, 2022. For more on the SUNL Lawsuit please contact us today.
According to the Sunlight lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective underwriting and risk evaluation with respect to its contractor advance program; (2) Sunlight lacked the oversight and periodic monitoring systems necessary to timely detect bad debt associated with its contractor advance program; (3) the Company lacked effective internal controls over accounting and reporting of non-cash advance receivables; (4) as a result, the Company would be forced to take a non-cash advance receivables impairment charge exceeding $30 million; and (5) as a result of the foregoing, defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Sunlight you have until February 14, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TWST class action lawsuit has been filed on behalf of investors who purchased Twist Bioscience Corporation (TWST) securities between December 13, 2019, and November 14, 2022. For more on the TWST Lawsuit please contact us today.
According to the Twist Bioscience lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: 1) as alleged in the November 15, 2022 report by Scorpion Capital, defendants overstated the commercial viability of Twist’s synthetic DNA manufacturing technology, and 2) at the same time, defendants were engaging in accounting fraud and using unsustainable pricing to inflate the Company’s true financial condition and prospects.
If you suffered a loss in Twist Bioscience you have until February 10, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SGLY class action lawsuit has been filed on behalf of investors who purchased Singularity Future Technology Ltd. (SGLY) securities between February 12, 2021, and November 17, 2022 For more on the SGLY Lawsuit please contact us today.
According to the Singularity lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had misrepresented the true educational background of its former CEO, Yang Jie; 2) Yang Jie had an outstanding arrest warrant in China, had committed forgery, and was the largest shareholder and VP of Finance for a Nasdaq-listed lending company, China Commercial Credit (“CCC”), which failed after reporting massive losses; (3) there existed material related party transactions with SOS Information Technology New York Inc. (where Jie’s wife was Vice President) and Rich Trading, whose CEO was defendant Lei Nie, the husband of Singularity CFO Tuo Pan; (4) Singularity director John Levy had been a director at CCC from January 2013 through December 2016 as CCC failed amidst detailed allegations that Jie, when he was an executive and shareholder in CCC, misappropriated assets; (5) the Company lacked adequate internal controls, and as a result had a heightened risk of scrutiny and was ultimately subject to a United States Attorney’s Office for the Southern District of New York and SEC investigation and action as well as a potential delisting by NASDAQ; and (6) as a result, the Company’s statements during the class period about the historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company, and were materially false and misleading and lacked a factual basis.
If you suffered a loss in Singularity you have until February 7, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an NBEVQ class action lawsuit has been filed on behalf of investors who purchased NewAge, Inc. (NBEVQ) securities between January 18, 2018, and October 18, 2022. For more on the NBEVQ Lawsuit please contact us today.
According to the NewAge lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company and defendants had no relationship with the military or FamilyMart; (2) the Company and defendants overstated the business agreements that they did have; (3) the Company and defendants never produced or sold a proprietary CBD beverage; (4) the Company lacked adequate internal controls; (5) as a result the Company had a heightened risk of regular scrutiny and ultimately subject to an SEC investigation and action; and (6) as a result of the foregoing, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in NewAge you have until February 6, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AFRM class action lawsuit has been filed on behalf of investors who purchased Affirm Holdings, Inc. (AFRM) securities between February 12, 2021, and December 15, 2021. For more on the AFRM Lawsuit please contact us today.
According to the Affirm lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Affirm’s “buy-now, pay-later” service facilitated excessive consumer debt, regulatory arbitrage, and data harvesting; (ii) the foregoing subjected Affirm to a heightened risk of regulatory scrutiny and enforcement action; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Affirm you have until February 6, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a SI class action lawsuit has been filed on behalf of investors who purchased Silvergate Capital Corporation (SI) securities between November 9, 2021, and November 17, 2022. For more on the SI Lawsuit please contact us today.
According to the Silvergate lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s platform lacked sufficient controls and procedures to detect instances of money laundering; (2) Silvergate’s customers had engaged in money laundering in amounts exceeding $425 million; (3) as a result of the foregoing, the Company was reasonably likely to receive regulatory scrutiny and face damages, including penalties and reputational harm; and (4) as a result of the foregoing, defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Silvergate you have until February 6, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an FXLV class action lawsuit has been filed on behalf of investors who purchased F45 Training Holdings Inc. (FXLV) This lawsuit is on behalf of all persons and entities that purchased or otherwise acquired the common stock of F45 pursuant and/or traceable to documents issued in connection with the Company’s July 16, 2021 initial public offering. For more on the FXLV Lawsuit please contact us today.
According to the F45 Training lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: 1) F45 Training could not maintain new franchise growth because it was offering more favorable payment terms to multi-unit franchisees; 2) F45 Training’s lackluster pace of growth was also accompanied by a massive and unsustainable increase in F45 Training’s accounts receivable and a similar, and equally unsustainable, decrease in its cash and cash equivalents; and 3) these practices were not sustainable at the time of the initial public offering, and when F45 Training could no longer sustain this defective business model, its growth rate and revenue plummeted.
If you suffered a loss in F45 Training you have until February 6, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an IREN class action lawsuit has been filed on behalf of investors who purchased Iris Energy Limited (IREN) This lawsuit is on behalf of a class consisting of all persons and entities other than the defendants that purchased or otherwise acquired: (a) Iris ordinary shares pursuant and/or traceable to the documents issued in connection with the Company’s initial public offering conducted on or about November 17, 2021; and/or (b) Iris securities between November 17, 2021, and November 1, 2022, both dates inclusive. For more on the IREN Lawsuit please contact us today.
According to the Iris Energy Limited lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) certain of Iris’s Bitcoin miners, owned through its wholly-owned special purpose vehicles, were unlikely to produce sufficient cash flow to service their respective debt financing obligations; (ii) accordingly, Iris’s use of equipment financing agreements to procure Bitcoin miners was not as sustainable as defendants had represented; (iii) the foregoing was likely to have a material negative impact on the Company’s business, operations, and financial condition; and (iv) as a result, documents issues in connection with the Company’s initial public offering and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
If you suffered a loss in Iris Energy Limited you have until February 6, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a GPS class action lawsuit has been filed on behalf of investors who purchased The Gap, Inc. (GPS) securities between November 24, 2021, and July 11, 2022. For more on the GPS Lawsuit please contact us today.
According to The Gap lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(1) there were execution missteps in size and assortment at Old Navy related to BODEQUALITY, the Company’s size-inclusivity campaign, which was adversely impacting Old Navy’s margins and financial results; (2) contrary to the Company’s statements, there were inventory risks relating to BODEQUALITY that were adversely affecting the Company’s operations; and as a result (3) the Company’s statements during the class period about the historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company, and were materially false and misleading and lacked a factual basis.
If you suffered a loss in The Gap you have until February 3, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a GNRC class action lawsuit has been filed on behalf of investors who purchased Generac Holdings Inc. (GNRC) securities between April 29, 2021, and November 1, 2022 For more on the GNRC Lawsuit please contact us today.
According to the Generac lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) despite the defendant’s claims that “safety is paramount”, Generac’s SnapRS units, which are components for rapidly shutting down solar devices in certain dangerous situations, were defective; (2) Generac did not timely record warranty liabilities resulting from the defective SnapRS units; and, (3) despite assurances to the contrary, the Company’s sales to channel partners were highly concentrated in a single partner.
If you suffered a loss in Generac you have until January 30, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SPPI class action lawsuit has been filed on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (SPPI) securities between December 6, 2021, through September 22, 2022 For more on the SPPI Lawsuit please contact us today.
According to the Spectrum lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint, defendants were conducting a phase 2 clinical trial called ZENITH20, which was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumour effects, safety, and tolerability of poziotinib in patients with locally advanced or metastatic non-small cell lung cancer that have certain mutations and were previously treated with the standard of care. Although the defendants represented that the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study, on September 20, 2022, a briefing document from the United States Food and Drug Administration Oncologic Drugs Advisory Committee disclosed not only negative data on the safety and efficacy of poziotinib but also a failure by the Company to enrol any patients in a required phase 3 confirmatory trial.
If you suffered a loss in Spectrum you have until February 3, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a NEO class action lawsuit has been filed on behalf of investors who purchased NeoGenomics, Inc. (NEO) securities between February 27, 2020, and April 26, 2022. For more on the NEO Lawsuit please contact us today.
According to the NeoGenomics lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a “comprehensive menu” of cancer tests with “every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing,” which positioned the Company as a “one-stop-shop” for pathologists and gave NeoGenomics “a competitive advantage” as a “go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer”; and (2) defendants represented that NeoGenomics could “leverage” the supposedly “fixed cost” structure of its business to improve profitability as revenue increased and touted the Company’s “robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business.”
If you suffered a loss in NeoGenomics you have until February 6, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a VERU class action lawsuit has been filed on behalf of investors who purchased Veru Inc. (VERU) securities between May 11, 2022, and November 9, 2022 For more on the VERU Lawsuit please contact us today.
According to the Veru lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company’s interactions with the United States Food and Drug Administration; 2) defendants misled Veru’s shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization (“EUA”) and even the submission of a New Drug Application without any further studies; and 3) the Company’s filings concealed the true risks faced by Veru in gaining approval for its EUA request.
If you suffered a loss in Veru you have until February 6, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a VWE class action lawsuit has been filed on behalf of investors who purchased Vintage Wine Estates, Inc. (VWE) securities between October 13, 2021, and September 13, 2022. For more on the VWE Lawsuit please contact us today.
According to the Vintage Wine lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) due to a material weakness related to its inventory controls and procedures, the Company lacked a reasonable basis to report inventory metrics; (2) the Company understated its overhead burden in certain quarters, thereby overstating its adjusted EBITDA; (3) as a result of the foregoing, Vintage Wine was reasonably likely to incur significant charges to restate prior reporting; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Vintage Wine you have until January 13, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
Levi & Korsinsky, LLP announces that an OLPX class action lawsuit has been filed on behalf of investors who purchased Olaplex Holdings, Inc. (OLPX) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Olaplex common stock pursuant and/or traceable to the Company’s initial public offering conducted on or around September 30, 2021. For more on the OLPX Lawsuit please contact us today.
According to the Olaplex lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) macroeconomic pressures and competition in the haircare market were more robust than the Company had represented to investors; (ii) accordingly, the Company was unlikely to maintain its sales and revenue momentum; and (iii) as a result, it was unlikely that the Company would be able to achieve the financial and operational growth projected in the offering documents; and (iv) as a result, the offering documents were materially false and/or misleading and failed to state information required to be stated therein.
If you suffered a loss in Olaplex you have until January 17, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CORZ class action lawsuit has been filed on behalf of investors who purchased Core Scientific, Inc. (CORZ) securities between January 3, 2022, and October 26, 2022. For more on the CORZ Lawsuit please contact us today.
According to the Core Scientific lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) due in part to the expiration of a favorable pricing agreement, the Company was experiencing increasing power costs; (2) the Company’s largest customer, Gryphon Digital Mining, lacked the financial resources to purchase the necessary miner rigs for Core Scientific to host; (3) the Company was not providing hosting services to Celsius Network LLC (“Celsius”) as required by their contract; (4) the Company had implemented an improper surcharge to pass through power costs to Celsius; (5) as a result of the foregoing alleged breaches of contract, the Company was reasonably likely to incur liability to defend itself against Celsius; (6) as a result of the foregoing, the Company’s profitability would be adversely impacted; (7) as a result, there was likely substantial doubt as to the Company’s ability to continue as a going concern; and (8) as a result of the foregoing, defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Core Scientific you have until January 13, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a RENT class action lawsuit has been filed on behalf of investors who purchased Rent the Runway, Inc. (RENT) This lawsuit is on behalf of all persons or entities who purchased Rent the Runway Class A common stock in or traceable to the Company’s October 2021 initial public offering. For more on the RENT Lawsuit please contact us today.
According to the Rent the Runway lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Rent the Runway was continuing to face extraordinary business headwinds, such as transportation headwinds and labor wage rate increases, from the COVID-19 pandemic; (ii) Rent the Runway’s active subscriber enrollments had sharply decelerated from the growth trajectory represented in the offering documents and, as a result, Rent the Runway was several months away from approaching its pre-pandemic levels of active subscriptions; (iii) Rent the Runway needed to substantially increase marketing and advertising costs from historical figures in order to attempt to grow its active subscriber network; (iv) Rent the Runway was suffering from ballooning fulfillment and transportation costs; and (v) as a result, Rent the Runway was suffering accelerating operational losses at the time of the initial public offering and was far less likely to achieve profitability in the near term, if ever, than represented.
If you suffered a loss in Rent the Runway you have until January 13, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a UIS class action lawsuit has been filed on behalf of investors who purchased Unisys Corporation (UIS) securities between August 3, 2022, and November 7, 2022. For more on the UIS Lawsuit please contact us today.
According to the Unisys lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(i) the Company’s 2022 financial guidance was significantly overstated; (ii) accordingly, once the truth was revealed, it was likely that the Company would be required to negatively revise its 2022 financial guidance; (iii) in addition to the foregoing, material weaknesses existed in the Company’s internal control over financial reporting; and (iv) as a result of all of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Unisys you have until January 10, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TSP class action lawsuit has been filed on behalf of investors who purchased TuSimple Holdings Inc. (TSP) This lawsuit is on behalf of all persons who: (a) purchased or otherwise acquired TuSimple securities pursuant and/or traceable to documents issued in connection with TuSimple’s April 15, 2021, initial public offering; and/or (b) purchased or otherwise acquired TuSimple securities between April 15, 2021, and October 31, 2022, both dates inclusive. For more on the TSP Lawsuit please contact us today.
According to the TuSimple lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) TuSimple was engaged in undisclosed related party transactions with Hydron, a company founded by TuSimple’s co-founder, Mo Chen; (2) TuSimple shared confidential information and/or proprietary technology with Hydron without the approval of TuSimple’s board of directors or informing regulators or TuSimple shareholders; (3) TuSimple failed to disclose the internal investigation by its board of directors into the Company’s ties to Hydron, which commenced in July 2022; (4) the aforementioned conduct enhanced the likelihood of regulatory scrutiny and investigatory action toward the Company; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in TuSimple you have until January 9, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CURV class action lawsuit has been filed on behalf of investors who purchased Torrid Holdings Inc. (CURV) This lawsuit is on behalf of all persons who purchased Torrid common stock in or traceable to the Company’s July 2021 initial public offering. For more on the CURV Lawsuit please contact us today.
According to the Torrid lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) in the first half of 2021, Torrid had experienced a temporary surge in demand as a result of changed consumer behaviors in response to the COVID-19 pandemic and government stimulus and that such ephemeral demand trends had dissipated and were not internally projected to continue following the initial public offering (“IPO”); (ii) Torrid was suffering from severe supply chain disruptions caused by the emergence of the Delta variant of COVID-19, which had first emerged in May 2021; (iii) Torrid was running materially below historical inventory levels as a result of supply chain disruptions; (iv) as a result, Torrid did not have sufficient inventory to meet expected consumer demand for its fiscal third quarter of 2021; (v) as a result, late inventory arrival had materially impaired the Company from effectively matching consumer buying trends, creating an undisclosed risk of increased markdowns and promotional activities necessary to sell undesirable inventory; (vi) Torrid’s Chief Financial Office planned to retire shortly after the IPO; and (vii) as a result of the above, representations made in the Company’s registration statement regarding Torrid’s historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, financial results, and trajectory of the Company at the time of the IPO, and were materially false and misleading and lacked a reasonable factual basis.
If you suffered a loss in Torrid you have until January 16, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an EIGR class action lawsuit has been filed on behalf of investors who purchased Eiger BioPharmaceuticals, Inc. (EIGR) securities between March 10, 2021, and October 4, 2022. For more on the EIGR Lawsuit please contact us today.
According to the Eiger lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger’s clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization (“EUA”) for the Company’s product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Eiger you have until January 9, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a SEDG class action lawsuit has been filed on behalf of investors who purchased SolarEdge Technologies, Inc. (SEDG) securities between August 6, 2022, and October 19, 2022, For more on the SEDG Lawsuit please contact us today.
According to the SolarEdge lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the designs of the power optimizers, inverters, and components thereof used to develop SolarEdge’s products potentially originated with and were misappropriated from Ampt LLC (“Ampt”), a competitor in the renewable energy industry; (ii) Ampt made claims against the Company for misappropriating Ampt’s patented technology, (iii) evidentiary support existed for the allegations that SolarEdge misappropriated certain patents relating to the design and development of the Company’s power optimizers and inverters; (iv) as a result, SolarEdge faced a threat of regulatory and/or court action, which could prohibit the import, marketing, and sale of its power optimizers and inverters, including solar energy systems that contain such products; which in turn (v) seriously threatened SolarEdge’s ability to monetize on their solar energy systems that contain the power optimizers and inverters in the United States and generate revenue; and (vi) certain revenues generated from the sale of power optimizers and inverters were potentially based on SolarEdge’s unlawful activities, including the misappropriation of patented designs by Ampt.
If you suffered a loss in SolarEdge you have until January 3, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an EVA class action lawsuit has been filed on behalf of investors who purchased Enviva Inc. (EVA) securities between February 21, 2019, and October 11, 2022 For more on the EVA Lawsuit please contact us today.
According to the Enviva lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Enviva had misrepresented the environmental sustainability of its wood pellet production and procurement; (ii) Enviva had similarly overstated the true measure of cash flow generated by the Company’s platform; (iii) accordingly, Enviva had misrepresented its business model and the Company’s ability to achieve the level of growth that defendants had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Enviva you have until January 3, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an FRSH class action lawsuit has been filed on behalf of investors who purchased Freshworks Inc.(FRSH) This lawsuit is on behalf of persons and entities that purchased Freshworks common stock pursuant to and/or traceable to documents issued in connection with the Company’s initial public offering. For more on the FRSH Lawsuit please contact us today.
According to the Freshworks lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the complaint, the documents used to effectuate Freshworks’ initial public offering were false and misleading and omitted to state that, at the time of the initial public offering, the Company’s business had encountered obstacles. As a result of these obstacles, Freshworks’ net dollar retention rate was plateauing, and its revenue growth rate and billings were decelerating.
If you suffered a loss in Freshworks you have until January 3, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a POL class action lawsuit has been filed on behalf of investors who purchased Polished.com Inc. f/k/a 1847 Goedeker Inc. (POL) This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Polished securities: (1) pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company’s 2020 initial public offering; and/or (2) between July 27, 2020, and August 25, 2022, inclusive. For more on the POL Lawsuit please contact us today.
According to the Polished lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company would restate certain financials; (2) the Company’s internal controls were inadequate; (3) the Company downplayed and obfuscated its internal controls issues; (4) as a result, the Company would engage in an independent investigation; (5) as a result of the investigation, the Company would, among other things, retain independent counsel and consultants, and delay its quarterly filings in violation of NYSE requirements of listing; (6) following the commencement of the investigation, the Company’s CEO and CFO would leave the Company; and (7) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in Polished you have until December 30, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a FIGS class action lawsuit has been filed on behalf of investors who purchased FIGS, Inc. (FIGS) This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired: (i) FIGS securities between May 27, 2021, and May 12, 2022, inclusive; and/or (ii) FIGS stock pursuant and/or traceable to documents issued in connection with FIGS’ initial public offering. For more on the FIGS Lawsuit please contact us today.
According to the FIGS lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants had inflated the Company’s true ability to successfully secure repeat customers; (ii) defendants had failed to disclose the Company’s increasing dependence on air freight; (iii) defendants had inflated the expected net revenues, gross margin, and adjusted EBITDA margin for 2022; and (iv) as a result of the foregoing, defendant’s statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in FIGS you have until January 3, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a USB class action lawsuit has been filed on behalf of investors who purchased U.S. Bancorp (USB) securities between August 1, 2019, and July 28, 2022. For more on the USB Lawsuit please contact us today.
According to the U.S. Bancorp lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) U.S. Bank created sales pressure on its employees that led them to open credit cards, lines of credit, and deposit accounts without consumers’ knowledge and consent; (b) since at least 2015, U.S. Bank and by extension, U.S. Bancorp, was aware of such unauthorized conduct and that it was violating relevant regulations and laws aimed at protecting its consumers; (c) U.S. Bancorp failed to properly monitor its employees from engaging in such unlawful conduct, detect and stop the misconduct, and identify and remediate harmed consumers; (d) all the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny or investigation; (e) U.S. Bancorp’s revenues were in part the product of unlawful conduct and thus unsustainable; and (f) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in U.S. Bancorp you have until December 27, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CMP class action lawsuit has been filed on behalf of investors who purchased Compass Minerals International, Inc. (CMP) securities between October 31, 2017, and November 18, 2018. For more on the CMP Lawsuit please contact us today.
According to the Compass Minerals lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: 1) costs at the Company’s salt mine in Goderich, Ontario were increasing rather than decreasing; 2) defendants had misrepresented the amount of salt the Company was able to produce at Goderich using the new continuous mining and continuous haulage equipment, and 3) the known and ongoing production shortfalls the Company was experiencing were reasonably expected to reduce its future operating income.
If you suffered a loss in Compass Minerals you have until December 20, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ARGO class action lawsuit has been filed on behalf of investors who purchased Argo Group International Holdings, Ltd. (ARGO) securities between February 13, 2018, and August 9, 2022. For more on the ARGO Lawsuit please contact us today.
According to the Argo lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Argo’s reserves were wholly inadequate and its underwriting standards were not prudent as was represented; (ii) Argo had dramatically changed its underwriting policies on certain U.S. construction contracts as far back as 2018; and (iii) these policies were underwritten outside of the Company’s “core” business including in certain states and for certain exposures that were far riskier than investors understood and that the Company no longer would service moving forward.
If you suffered a loss in Argo you have until December 20, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a RAD class action lawsuit has been filed on behalf of investors who purchased Rite Aid Corporation (RAD) securities between April 14, 2022, and September 28, 2022. For more on the RAD Lawsuit please contact us today.
According to the Rite Aid lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) despite representations to the contrary, the number of new members that the Elixir pharmacy benefit management services business was adding during the selling season ending on January 1, 2023, was in material decline; (ii) Rite Aid was likely to recognize a significant charge for the impairment of goodwill related to Elixir due to a decrease in “lives” covered by Elixir’s pharmacy benefit management services business; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Rite Aid you have until December 19, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an IGT class action lawsuit has been filed on behalf of investors who purchased International Game Technology PLC (IGT) securities between March 16, 2018, and August 29, 2022. For more on the IGT Lawsuit please contact us today.
According to the IGT lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) IGT overstated its compliance with gaming and lottery laws and applicable regulations; (ii) IGT and/or one or more of its current and/or former subsidiaries engaged in illegal gambling operations; (iii) the foregoing conduct subjected the Company and/or its current and/or former subsidiaries to a heightened risk of litigation and significant related costs; (iv) the Company downplayed the full scope and severity of its financial exposure to, and/or liabilities in connection with, the lawsuit filed against IGT’s subsidiary in April of 2018; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in IGT you have until December 13, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an OPEN class action lawsuit has been filed on behalf of investors who purchased Opendoor Technologies Incorporated (OPEN) This lawsuit is on behalf of a class consisting of all persons and entities other than the defendants that purchased or otherwise acquired: (a) Opendoor securities between December 21, 2020, and September 16, 2022, both dates inclusive and/or (b) Opendoor common stock pursuant and/or traceable to documents issued in connection with the business combination between the Company and Opendoor Labs Inc. completed on or about December 18, 2020. For more on the OPEN Lawsuit please contact us today.
According to the Opendoor lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the algorithm used by the Company to make offers for homes could not accurately adjust to changing house prices across different market conditions and economic cycles; (ii) as a result, the Company was at an increased risk of sustaining significant and repeated losses due to residential real estate pricing fluctuations; (iii) accordingly, defendants overstated the purported benefits and competitive advantages of the algorithm; (iv) as a result, documents issued in connection with the merger between the Company and Opendoor Labs Inc. and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
If you suffered a loss in Opendoor you have until December 6, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SQ class action lawsuit has been filed on behalf of investors who purchased Block, Inc.(SQ) securities between November 4, 2021, and April 4, 2022. For more on the SQ Lawsuit please contact us today.
According to the block lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate protocols restricting access to customer sensitive information; (2) as a result, a former employee was able to download certain reports of the Company’s subsidiary, Cash App Investing, containing full customer names and brokerage account numbers, as well as brokerage portfolio value, brokerage portfolio holdings and/or stock trading activity; (3) as a result, the Company was reasonably likely to suffer significant damage, including reputational harm; (4) and as a result of the foregoing, defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in the block you have until December 12, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a PYPL class action lawsuit has been filed on behalf of investors who purchased PayPal Holdings, Inc (PYPL) securities between February 3, 2021, and February 1, 2022. For more on the PYPL Lawsuit please contact us today.
According to the PayPal Holdings lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants had inflated the Company’s vitally important Net New Active Accounts metric guidance through a usually large use of marketing campaigns that were quickly susceptible to fraud; i.e. the creation of millions of illegitimate accounts which were created for the sole purpose of taking advantage of cash incentives for account creation; (2) defendants used these marketing campaigns and other incentives to hide the Company’s true churn rate and declining levels of engagement with the platform; and (3) as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.
If you suffered a loss in PayPal Holdings you have until December 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CNTA class action lawsuit has been filed on behalf of investors who purchased Centessa Pharmaceuticals plc (CNTA) This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021, and June 1, 2022. For more on the CNTA Lawsuit please contact us today.
According to the Centessa lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan’s clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874’s clinical and commercial prospects while downplaying the drug’s safety issues; and (v) as a result, documents issued in connection with Centessa’s initial public offering and the Company’s public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
If you suffered a loss in Centessa you have until November 28, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an OLO class action lawsuit has been filed on behalf of investors who purchased Olo Inc. (OLO) securities between August 11, 2021, and August 11, 2022.For more on the OLO Lawsuit please contact us today.
According to the Olo lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Subway was ending its contract with Olo; (2) Olo’s key business metric – active locations – could not continue to grow as defendants touted due to the loss of Subway’s business; and (3) as a result of the above, defendants’ statements about Olo’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Olo you have until November 28, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a YSG class action lawsuit has been filed on behalf of investors who purchased Yatsen Holding Limited (YSG) This lawsuit is on behalf of a class consisting of all persons and entities who purchased Yatsen Holding Limited American Depository Shares (“ADS”) between November 19, 2020 and March 10, 2022, or acquired Yatsen ADS pursuant or traceable to documents issued in connection with Yatsen’s November 2020 initial public stock offering. For more on the YSG Lawsuit please contact us today.
According to the Yatsen lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: The filed complaint alleges that defendants made false statements and/or concealed that the registration statement and prospectus used to effectuate the Company’s initial public offering (“IPO”), Yatsen and the other named defendants misled investors into believing that Yatsen’s most significant brands, Perfect Diary and Little Ondine, were thriving, thereby driving Yatsen’s “healthy” top-line growth at the time of its IPO and quarter after quarter thereafter. In truth, however, cosmetic and skincare sales of Perfect Diary and Little Ondine products were declining in the period leading up to (and including at the time of) the IPO and throughout 2021. Moreover, as the truth about Yatsen’s business reached the market, the value of the Company’s shares declined dramatically, causing Yatsen investors to suffer significant damages.
If you suffered a loss in Yatsen you have until November 22, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a BCS class action lawsuit has been filed on behalf of investors who purchased Barclays PLC (BCS) This lawsuit is on behalf of persons who purchased or otherwise acquired Barclays American Depositary Receipts on a U.S. open market between February 18, 2021, and March 25, 2022. For more on the BCS Lawsuit please contact us today.
According to the Barclays lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: a) as of December 31, 2020, and February 18, 2021, Barclays had a material weakness in its internal control environment due to the fact that the over-issuance had occurred and was not immediately identified; and b) they failed to disclose that as of February 18, 2021 (i) Barclays Bank PLC (“BBPLC”) had and was selling unregistered securities in excess of the amounts registered by the August 2019 shelf registration statement, (ii) BBPLC was violating U.S. securities laws and/or the U.S. Securities and Exchange Commission regulations, subjecting Barclays to legal liability, and (iii) BBPLC was required to conduct a rescission offer for those unregistered securities.
If you suffered a loss in Barclays you have until November 22, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an FLGT class action lawsuit has been filed on behalf of investors who purchased Fulgent Genetics, Inc. (FLGT) securities between March 22, 2019, and August 4, 2022. For more on the FLGT Lawsuit please contact us today.
According to the Fulgent lawsuit, throughout the Class Period defendants made false and misleading statements and failed to disclose that: (i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent’s revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Fulgent you have until November 21, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a PLTR class action lawsuit has been filed on behalf of investors who purchased Palantir Technologies Inc. (PLTR) securities between November 9, 2021, and May 6, 2022. For more on the PLTR Lawsuit please contact us today.
According to the Palantir lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Palantir’s investments in marketable securities were having a significant negative impact on the Company’s earnings per share (“EPS”) results; (ii) Palantir overstated the sustainability of its government segment’s growth and revenues; (iii) Palantir was experiencing a significant slowdown in revenue growth, particularly among its government customers, despite ongoing global conflicts and market disruptions; (iv) as a result of all the foregoing, the Company was likely to miss consensus estimates for its first quarter 2022 EPS and second quarter 2022 sales outlook; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Palantir you have until November 14, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TWTR class action lawsuit has been filed on behalf of investors who purchased Twitter, Inc. (TWTR) securities between August 3, 2020, and August 23, 2022. For more on the TWTR Lawsuit please contact us today.
According to the Twitter lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Twitter knew about security concerns on their platform; (2) Twitter actively worked to hide the security concerns from the board, the investing public, and regulators; (3) contrary to representations in its filings with the U.S. Securities and Exchange Commission, Twitter did not take steps to improve security; (4) Twitter’s active refusal to address security issues increased the risk of loss of public goodwill; and (5) as a result, defendants’ statements about Twitter’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Twitter you have until November 14, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an MDT class action lawsuit has been filed on behalf of investors who purchased Medtronic plc (MDT) securities between June 8, 2019, and May 25, 2022. For more on the MDT Lawsuit please contact us today.
According to the Medtronic plc lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Medtronic’s product quality control systems were inadequate; (2) Medtronic had failed to comply with numerous regulations regarding risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events; (3) these failures increased the risk of regulatory investigation and action; (4) as a result of the Company’s misconduct, the U.S. Food and Drug Administration would delay the approval of additional Medtronic MiniMed devices, including the MiniMed 780G; (5) these delays in product approvals, as well as the Company’s need to improve its quality control systems, would negatively affect the Company’s financial performance and cause Medtronic to fall further behind its competitors; and (6) as a result of the foregoing, defendant’s statements about the Company’s business, operations, and prospects lacked a reasonable basis.
If you suffered a loss in Medtronic plc you have until November 7, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SMFR class action lawsuit has been filed on behalf of investors who purchased Sema4 Holdings, Corp. (SMFR) securities between March 14, 2022, and August 15, 2022. For more on the SMFR Lawsuit please contact us today.
According to the Sema4 Holdings, Corp. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) there was a significant risk that Sema4 would reverse a material amount of previously recognized revenue that it could not recoup from third-party payors; (2) the Company was experiencing declining selling prices for its reproductive health segment; (3) as a result of the foregoing, Sema4’s financial results would be adversely affected; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and lacked a reasonable basis.
If you suffered a loss in Sema4 Holdings, Corp. you have until November 7, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ABT class action lawsuit has been filed on behalf of investors who purchased Abbott Laboratories (ABT) This lawsuit is on behalf of all persons or entities who purchased or otherwise acquired shares of Abbott common stock during the period from February 19, 2021, to June 8, 2022, For more on the ABT Lawsuit please contact us today.
According to the Abbott Laboratories lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: the defendants touted the strength of Abbott’s infant formula brands and their contribution to the Company’s sales and revenue growth, despite knowing that the facility that manufactured those products was in flagrant violations of United States Food and Drug Administration (“FDA”) health, safety, and manufacturing regulations. The complaint further alleges that the defendants willfully or recklessly concealed these violations from investors, even though the violations put Abbott’s infant formula business in dire jeopardy and left the Company exposed to a risk of severe regulatory action, including the recall of its products and closure of the Sturgis facility. Indeed, according to the complaint, the defendants received direct warnings, communications, FDA inspection reports, and consumer complaints identifying in detail the safety and regulatory violations that were rampant at the Sturgis
If you suffered a loss in Abbott Laboratories you have until October 31, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a KSS class action lawsuit has been filed on behalf of investors who purchased Kohl’s Corporation (KSS) securities between October 20, 2020, and May 19, 2022 For more on the KSS Lawsuit please contact us today.
According to the Kohl’s Corporation lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Kohl’s new strategic framework to “drive top-line growth,” “expand operating margin,” and become “the most trusted retailer of choice for the active and casual lifestyle” (the “Strategic Plan”) was not well tailored to achieving the Company’s stated goals; (ii) the defendants had likewise overstated the Company’s success in executing its Strategic Plan; (iii) Kohl’s had deficient disclosure controls and procedures, internal control over financial reporting, and corporate governance mechanisms; (iv) as a result, the Company’s board of directors was able to and did withhold material information from shareholders about the state of Kohl’s in the lead-up to the Company’s annual meeting; (v) all the foregoing, once revealed, was likely to have a material adverse impact on Kohl’s financial condition and reputation; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Kohl’s Corporation you have until November 1, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TSP class action lawsuit has been filed on behalf of investors who purchased TuSimple Holdings Inc. (TSP) This lawsuit is on behalf of all persons who: (a) purchased or otherwise acquired TuSimple common stock pursuant and/or traceable to documents issued in connection with TuSimple’s April 15, 2021, initial public offering; and/or (b) that purchased or otherwise acquired TuSimple securities between April 15, 2021, and August 1, 2022, both dates inclusive. For more on the TSP Lawsuit please contact us today.
According to the TuSimple Holdings lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) TuSimple’s commitment to safety was significantly overstated and defendants concealed fundamental problems with the Company’s technology; (ii) TuSimple was rushing the testing of its autonomous driving technology in order to deliver driverless trucks to the market ahead of its more safety-conscious competitors; (iii) there was a corporate culture within TuSimple that suppressed or ignored safety concerns in favour of unrealistically ambitious testing and delivery schedules; (iv) the aforementioned conduct made accidents involving the Company’s autonomous driving technology more likely; (v) the aforementioned conduct invited enhanced regulatory scrutiny and investigatory action toward the Company; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in TuSimple Holdings you have until October 31, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AZRE class action lawsuit has been filed on behalf of investors who purchased Azure Power Global Limited (AZRE) securities between June 15, 2021, and August 26, 2022 For more on the AZRE Lawsuit please contact us today.
According to the Azure Power Global lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) there were procedural irregularities, including deviations from safety and quality standards, at one of Azure’s plants; (2) certain project data was manipulated; (3) as a result of the foregoing, the Company’s internal controls and procedures were not effective; (4) Azure had received a credible whistleblower report alleging such misconduct; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Azure Power Global you have until October 31, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an LTCH class action lawsuit has been filed on behalf of investors who purchased Latch, Inc. f/k/a TS Innovation Acquisitions Corp. (LTCH) securities between May 13, 2021, and August 25, 2022 For more on the LTCH Lawsuit please contact us today.
According to the Latch lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) there were unreported sales arrangements related to hardware devices; (2) as a result, the Company had improperly recognized revenue throughout fiscal 2021 and first quarter 2022; (3) there were material weaknesses in Latch’s internal control over financial reporting related to revenue recognition; (4) as a result of the preceding, Latch would restate financial statements for fiscal 2021 and first quarter 2022; and (5) as a result of the preceding, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Latch you have until October 31, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an NIO class action lawsuit has been filed on behalf of investors who purchased NIO Inc. (NIO) securities between March 1, 2021, and July 11, 2022. For more on the NIO Lawsuit please contact us today.
According to the NIO lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) NIO pulled forward revenue by selling batteries to a related party, which owned the batteries and managed users’ subscriptions; (2) through the related party, NIO also recognized enormous depreciation savings; (3) as a result of the foregoing, the Company’s revenue and net loss were overstated; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis
If you suffered a loss in NIO you have until October 24, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a DDL class action lawsuit has been filed on behalf of investors who purchased Dingdong (Cayman) Ltd. (DDL) This lawsuit is on behalf of persons who purchased or otherwise acquired, Dingdong American Depository Shares pursuant or traceable to the F-1 registration statements and related prospectus on Form 424B4 issued in connection with Dingdong’s June 2021 initial public stock offering. For more on the DDL Lawsuit please contact us today.
According to the Dingdong lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose: Omitted facts concerning Dingdong’s so-called commitment to ensuring the safety and quality of the food it distributes to the market. For example, despite claiming that it applies “stringent quality control across [its] entire supply chain to ensure product quality to [its] users,” Dingdong sold food past its sell-by date. Consequently, Dingdong was, in fact, no better at providing or assuring access to “fresh” groceries than the supermarkets, traditional Chinese wet markets, or traditional e-commerce platforms it repeatedly claimed to be displacing. Moreover, the foregoing conduct subjected Dingdong to an increased risk of regulatory and/or governmental scrutiny and enforcement, all of which, once revealed, were likely to negatively impact Dingdong’s business, operations, and reputation.
If you suffered a loss in Dingdong you have until October 24, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SFIX class action lawsuit has been filed on behalf of investors who purchased Stitch Fix, Inc. (SFIX) securities between December 8, 2020, and March 8, 2022, For more on the SFIX Lawsuit please contact us today.
According to the Stitch Fix lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: Stitch Fix made numerous false and misleading statements to investors concerning the synergy between the Company’s Fix and Freestyle programs, and repeatedly denied claims that the Freestyle program could cannibalize the Company’s legacy Fix business. Specifically, Stitch Fix repeatedly assured investors that the Company’s Freestyle business was “an additive experience” and “complementary” to the Fix business, that “the combination of those two things will allow us to address many more types of clients,” and that “we see solid growth in both sides of the business.” In truth, Stitch Fix concealed that these programs were not complementary or additive. Stitch Fix knew that the Freestyle program would be much preferred to the Company’s original Fix model and that the Freestyle program would inevitably cannibalize the Company’s legacy Fix business.
If you suffered a loss in Stitch Fix you have until October 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an HGEN class action lawsuit has been filed on behalf of investors who purchased Humanigen, Inc.(HGEN)securities between May 28, 2021, and July 12, 2022. For more on the HGEN Lawsuit please contact us today.
According to the Humanigen lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Humanigen’s lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than the defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab’s clinical and commercial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Humanigen you have until October 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an MNSO class action lawsuit has been filed on behalf of investors who purchased MINISO Group Holding Limited (MNSO) This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded MINISO securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with MINISO’s October 2020 initial public offering. For more on the MNSO Lawsuit please contact us today.
According to the MINISO lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants and other undisclosed related parties owned and controlled a much larger amount of MINISO stores than previously stated; (2) as a result, MINISO concealed its true costs; (3) the Company did not represent its true business model; (4) defendants, including the Company and its chairman, engaged in planned unusual and unclear transactions; (5) as a result of at least one of these transactions, the Company is at risk of breaching contracts with People’s Republic of China authorities; (6) the Company would imminently and drastically drop its franchise fees; and (7) as a result, defendant’s statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in MINISO you have until October 17, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CODX class action lawsuit has been filed on behalf of investors who purchased Co-Diagnostics, Inc. (CODX) This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022, through the close of the market on August 11, 2022 (4:00 p.m. ET). For more on the CODX Lawsuit please contact us today.
According to the Co-Dx lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) demand for the Company’s Logix Smart COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants’ positive statements about the demand for its Logix Smart COVID-19 test lacked a reasonable basis.
If you suffered a loss in Co-Dx you have until October 17, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AMPE class action lawsuit has been filed on behalf of investors who purchased Ampio Pharmaceuticals, Inc. (AMPE) This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired Ampio common stock between December 29, 2020, and August 3, 2022, inclusive. For more on the AMPE Lawsuit please contact us today.
According to the Ampio lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(i) defendants had inflated the Company’s true ability to successfully file a Biologics License Application (“BLA”) for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendant’s statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Ampio you have until October 17, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TUYA class action lawsuit has been filed on behalf of investors who purchased Tuya Inc. (TUYA)This lawsuit is on behalf of all persons or entities who purchased Tuya American Depositary Shares in or traceable to the Company’s March 2021 initial public offering For more on the TUYA Lawsuit please contact us today.
According to the Tuya lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) a material portion of Tuya’s China-based customers were engaged in the widespread and systematic manipulation of reviews and product offerings in violation of Amazon.com’s terms of use; (b) prior to the initial public offering, a consumer investigation and data breach had exposed an illicit fake review scheme being perpetrated by many of Tuya’s clients, among others, which included, inter alia, the exposure of 13 million records of organized fake review scams linked to over 200,000 Amazon account profiles; (c) as a result of (a) and (b) above, there was a substantial risk that a material portion of Tuya’s significant customers would be barred from using Amazon.com’s platform, negatively impacting Tuya’s business, revenue, earnings, and prospects; and (d) as a result of (a)-(c) above, the registration statement’s representations regarding Tuya’s historical financial and operational metrics and purported market opportunities and expected growth did not accurately reflect the actual business, operations, financial results, and trajectory of the Company at the time of the initial public offering, and such statements were materially false and misleading and lacked a reasonable factual basis.
If you suffered a loss in Tuya you have until October 11, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an LFST class action lawsuit has been filed on behalf of investors who purchased LifeStance Health Group, Inc. (LFST) This lawsuit is on behalf of all purchasers of LifeStance common stock pursuant and/or traceable to the documents issued in connection with LifeStance’s June 10, 2021, initial public stock offering. For more on the LFST Lawsuit please contact us today.
According to the LifeStance lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the number of virtual visits clients were undertaking utilizing LifeStance Health was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining LifeStance Health’s out-patient/virtual revenue growth; (ii) the percentage of in-person visits clients were undertaking utilizing LifeStance Health was increasing as the COVID-19 lockdowns were being lifted, thereby causing LifeStance Health’s operating expenses to increase substantially; (iii) LifeStance Health had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the initial public offering’s registration statement, and LifeStance Health had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (iv) as a result, LifeStance Health’s business metrics and financial prospects were not as strong as the initial public offering’s registration statement represented.
If you suffered a loss in LifeStance you have until October 11, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a KRBP class action lawsuit has been filed on behalf of investors who purchased Kiromic BioPharma, Inc. (KRBP) This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company’s public offering that closed on July 2, 2021, and/or (b) Kiromic common stock between June 25, 2021, and August 13, 2021, both dates inclusive. For more on the KRBP Lawsuit please contact us today.
According to the Kiromic lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: The complaint alleges that the registration statement and prospectus issued in connection with the Company’s public offering that closed on July 2, 2021 (the “Offering Documents”) failed to disclose that the Food and Drug Administration (“FDA”) had, prior to the filing of these documents, imposed a clinical hold on the Company’s Investigational New Drug (“IND”) applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.
If you suffered a loss in Kiromic you have until October 4, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CVNA class action lawsuit has been filed on behalf of investors who purchased Carvana Co.(CVNA) securities between May 6, 2020, and June 24, 2022 For more on the CVNA Lawsuit please contact us today.
According to the Carvana lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Carvana faced severe, ongoing issues with documentation, registration, and title with many of its vehicles; (2) as a result, Carvana was issuing unusually frequent temporary plates; (3) as a result of the foregoing, Carvana was violating laws and regulations in many existing markets; (4) as a result of the foregoing, Carvana risked its ability to continue business and/or expand its business in existing markets; (5) as a result of the foregoing, Carvana was at an increased risk of governmental investigation and action; (6) Carvana was in discussion with state and local authorities regarding the above-stated business tactics and issues; (7) Carvana was facing imminent and ongoing regulatory actions including license suspensions, business cessation, and probation in several states and counties including in Arizona, Illinois, Pennsylvania, Michigan, and North Carolina; and (8) as a result, Defendants’ statements about Carvana’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Carvana you have until October 3, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ENOB class action lawsuit has been filed on behalf of investors who purchased Enochian BioSciences, Inc.(ENOB) securities between January 17, 2018, and June 27, 2022. For more on the ENOB Lawsuit please contact us today.
According to the Enochian lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu’s purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Enochian you have until September 26, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a WEBR class action lawsuit has been filed on behalf of investors who purchased Weber Inc. (WEBR) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Weber Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s August 2021 initial public offering For more on the WEBR Lawsuit please contact us today.
According to the Weber lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(1) Weber was reasonably likely to implement price increases; (2) as a result, consumer demand for Weber’s products was reasonably likely to decrease; (3) due to the resulting inventory buildup, Weber was reasonably likely to run promotions to “enhance retail sell through”; (4) the foregoing would adversely impact Weber’s financial results; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Weber you have until September 27, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a YQ class action lawsuit has been filed on behalf of investors who purchased 17 Education & Technology Group Inc.(YQ) This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded 17EdTech securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with 17EdTech’s December 2020 initial public offering. For more on the YQ Lawsuit please contact us today.
According to the 17 Education & Technology Group lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) 17EdTech’s K-12 Academic AST Services would end less than a year after the Company’s initial public offering; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech’s core business; and (3) as a result, defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in 17 Education & Technology Group you have until September 19, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TGTX class action lawsuit has been filed on behalf of investors who purchased TG Therapeutics, Inc. (TGTX) securities between January 15, 2020, and May 31, 2022. For more on the TGTX Lawsuit please contact us today.
According to the TG Therapeutics lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company’s therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib’s clinical and/or commercial prospects; and (iv) therefore, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in TG Therapeutics you have until September 16, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an MF class action lawsuit has been filed on behalf of investors who purchased Missfresh Limited (MF) This lawsuit is on behalf of persons who purchased or otherwise acquired Missfresh securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Missfresh’s June 2021 initial public offering For more on the MF Lawsuit please contact us today.
According to the Missfresh lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Missfresh provided false financial figures in its registration statement and related prospectus issued in connection with the Company’s June 2021 initial public offering; (2) Missfresh would need to amend its financial figures; (3) Missfresh, among other things, had lesser net revenues for the quarter ended March 31, 2021; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times and negligently prepared.
If you suffered a loss in Missfresh you have until September 12, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a MOLN class action lawsuit has been filed on behalf of investors who purchased Molecular Partners AG (MOLN) This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022. For more on the MOLN Lawsuit please contact us today.
According to the Molecular Partners lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization (“EUA”); (iii) waning global rates of COVID-19 significantly reduced the Company’s chances of securing EUA for ensovibep; (iv) another of the Company’s product candidates, MP0310, was less attractive to Molecular Partners’ collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company’s initial public offer and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
If you suffered a loss in Molecular Partners you have until September 12, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AMZN class action lawsuit has been filed on behalf of investors who purchased Amazon.com, Inc.(AMZN) securities between July 30, 2021, and April 28, 2022, For more on the AMZN Lawsuit please contact us today.
According to the Amazon lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: 1) defendants knew or recklessly disregarded that the Company’s infrastructure and fulfilment network investments substantially outpaced demand; 2) those investments were a massive, self-imposed, undue drain on Amazon’s financial condition; 3) contrary to defendants’ public statements and undisclosed to investors, defendants had already implemented cutbacks to Amazon’s fulfilment capacity by July 2021; and 4) as a result of defendants’ misrepresentations and omissions, Amazon’s common stock traded at artificially inflated prices during the class period.
If you suffered a loss in Amazon you have until September 6, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a U class action lawsuit has been filed on behalf of investors who purchased Unity Software Inc. (U) securities between March 5, 2021, and May 10, 2022. For more on the U Lawsuit please contact us today.
According to the Unity lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) deficiencies in Unity’s product platform reduced the accuracy of the Company’s machine learning technology; (ii) the foregoing was likely to have a material negative impact on the Company’s revenues; (iii) accordingly, Unity had overstated the Company’s commercial and/or financial prospects for 2022; (iv) as a result, the Company was likely to have to reduce its fiscal 2022 guidance; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Unity you have until September 6, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an OM class action lawsuit has been filed on behalf of investors who purchased Outset Medical, Inc. (OM) securities between September 15, 2020, and June 13, 2022. For more on the OM Lawsuit please contact us today.
According to the Outset Medical lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(1) the Company’s flagship product, Tablo Hemodialysis System (“Tablo”), would require an additional 510(k) application to be filed with The United States Food and Drug Administration (“FDA”), as defendants had “continuously made improvements and updates to Tablo over time since its original clearance”; (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) the Company’s inability to perform the human factors study subjected the Company to the likelihood of the FDA imposing a “shipment hold” and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.
If you suffered a loss in Outset Medical you have until September 6, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a WFC class action lawsuit has been commenced on behalf of investors who purchased Wells Fargo & Company (WFC) securities between February 24, 2021 and June 9, 2022. For more on the WFC Class Action please contact us today.
According to the Wells Fargo lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Wells Fargo had misrepresented its commitment to diversity in the Company’s workplace; (ii) Wells Fargo conducted fake job interviews in order to meet its Diverse Search Requirement; (iii) the foregoing conduct subjected Wells Fargo to an increased risk of regulatory and/or governmental scrutiny and enforcement action, including criminal charges; (iv) all of the foregoing, once revealed, was likely to negatively impact Wells Fargo’s reputation; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Wells Fargo you have until August 29, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a NOTV class action lawsuit has been filed on behalf of investors who purchased Inotiv, Inc. (NOTV) securities between September 21, 2021, and June 13, 2022. For more on the NOTV Lawsuit please contact us today.
According to the Inotiv lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Inotiv’s acquisition, Envigo RMS, LL (“Envigo”), and Inotiv’s Cumberland, Virginia facility (the “Cumberland Facility”) engaged in widespread and flagrant violations of the Animal Welfare Act (“AWA”); (2) Envigo and Inotiv’s Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Inotiv you have until August 22, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a YEXT class action lawsuit has been filed on behalf of investors who purchased Yext, Inc.(YEXT) securities between March 4, 2021, and March 8, 2022. For more on the YEXT Lawsuit please contact us today.
According to the Yext lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Yext’s revenue and earnings were significantly deteriorating because of, among other things, poor sales execution and performance, as well as COVID-19 related disruptions; (ii) accordingly, Yext was unlikely to meet consensus estimates for its full-year fiscal 2022 financial results and fiscal 2023 outlook; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Yext you have until August 16, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an XRAY class action lawsuit has been filed on behalf of investors who purchased Dentsply Sirona Inc. (XRAY) securities between June 9, 2021, and May 9, 2022. For more on the XRAY Lawsuit please contact us today.
According to the Dentsply lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint, defendants orchestrated a scheme to inflate Dentsply’s revenue and earnings by manipulating the Company’s accounting for a distributor rebate program so that senior executives would be eligible for significant cash and stock-based incentive compensation. In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the class period. As a result of the defendants’ misrepresentations, Dentsply’s common stock was traded at artificially inflated prices during the class period.
If you suffered a loss in Dentsply you have until August 1, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TUP class action lawsuit has been filed on behalf of investors who purchased Tupperware Brands Corporation (TUP) securities between November 3, 2021, and May 3, 2022. For more on the TUP Lawsuit please contact us today.
According to the Tupperware lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Tupperware was facing significant challenges in maintaining its earnings and sales performance; (ii) accordingly, Tupperware’s full-year 2022 guidance was unrealistic and/or unsustainable; (iii) all the foregoing, once revealed, was likely to have a material negative impact on Tupperware’s financial condition; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Tupperware you have until August 15, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a UL class action lawsuit has been filed on behalf of investors who purchased Unilever PLC (UL) securities between September 2, 2020, and July 21, 2021 For more on the UL Lawsuit please contact us today.
According to the Unilever lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: a) in July 2020, the board of Ben & Jerry’s, one of Unilever’s marquee brands, passed a resolution to end sales of its ice cream in “Occupied Palestinian Territory”; and b) this boycott decision risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states.
If you suffered a loss in Unilever you have until August 15, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a WM class action lawsuit has been filed on behalf of investors who purchased Waste Management, Inc. (WM) securities between February 13, 2020, and June 23, 2020 For more on the WM Lawsuit please contact us today.
According to the Waste Management lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the U.S. Department of Justice had indicated to Waste Management that it would require Waste Management to divest significantly more assets than the $200 million indicated in the merger agreement between the Company and Advanced Disposal Services; (ii) as a result, the merger would not be completed by July 14, 2020, the end date under the merger agreement; and (iii) the Waste Management redeemable senior notes would be subject to mandatory redemption at 101% of par.
If you suffered a loss in Waste Management you have until August 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TDOC class action lawsuit has been filed on behalf of investors who purchased Teladoc Health, Inc. (TDOC) securities between October 28, 2021, and April 27, 2022. For more on the TDOC Lawsuit please contact us today.
According to the Teladoc lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) increased competition, among other factors, was negatively impacting Teladoc’s BetterHelp and chronic care businesses; (ii) accordingly, the growth of those businesses was less sustainable than Defendants had led investors to believe; (iii) as a result, Teladoc’s revenue and adjusted EBITDA projections for FY 2022 were unrealistic; (iv) as a result of all the foregoing, Teladoc would be forced to recognize a significant non-cash goodwill impairment charge; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Teladoc you have until August 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an APPS class action lawsuit has been filed on behalf of investors who purchased Digital Turbine, Inc. (APPS) securities between August 9, 2021, and May 17, 2022. For more on the APPS Lawsuit please contact us today.
According to the Digital Turbine lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines; (2) as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis; (3) the Company’s internal control over financial reporting as to revenue recognition was deficient; and (4) as a result of the foregoing, the Company’s net revenues was overstated throughout fiscal 2022; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Digital Turbineyou have until August 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an APYX class action lawsuit has been filed on behalf of investors who purchased Apyx Medical Corporation (APYX) securities between May 12, 2021, and March 11, 2022. For more on the APYX Lawsuit please contact us today.
According to the Apyx lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) a significant number of Apyx’s Advanced Energy products were used for off-label indications; (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events; (3) as a result, the Company was reasonably likely to incur regulatory scrutiny; (4) as a result of the foregoing, the Company’s financial results would be adversely impacted; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Apyx you have until August 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a VRCA class action lawsuit has been filed on behalf of investors who purchased Verrica Pharmaceuticals, Inc. (VRCA) securities between May 28, 2021, and May 24, 2022. For more on the VRCA Lawsuit please contact us today.
According to the Verricalawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(1) there were manufacturing deficiencies at the facility where Verrica’s contract manufacturer produced a bulk solution for the Company’s lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Verrica you have until August 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ET class action lawsuit has been filed on behalf of investors who purchased Energy Transfer LP (ET) securities between April 13, 2017, and December 20, 2021, For more on the ET Lawsuit please contact us today.
According to the Energy Transfer lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) Energy Transfer had inadequate internal controls and procedures to prevent contractors from engaging in illegal conduct with regards to drilling activities, and/or failed to adequately mitigate known issues related to such controls and procedures; (b) Energy Transfer, through its subsidiary Rover Pipeline, LLC, hired a third-party contractor to conduct Horizontal Directional Drilling Activities for the Rover Pipeline Project, whose conduct of adding illegal additives in the drilling mud caused severe pollution near the Tuscarawas River when a sizeable inadvertent release took place on April 13, 2017; (c) Energy Transfer continually downplayed its potential civil liabilities when the Federal Energy Regulatory Commission (“FERC”) was actively investigating the Energy Transfer’s wrongdoing related to the April 13 release and consistently provided it with updated information about FERC’s findings on this matter.
If you suffered a loss in Energy Transfer you have until August 2, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an IONQ class action lawsuit has been filed on behalf of investors who purchased IonQ, Inc.(IONQ) securities between March 30, 2021, and May 2, 2022. For more on the IONQ Lawsuit please contact us today.
According to the IonQ lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) IonQ had not yet developed a 32-qubit quantum computer; (2) the Company’s 11-qubit quantum computer suffered from significant error rates, rendering it useless; (3) IonQ’s quantum the computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers; (4) a significant portion of IonQ’s revenue was derived from improper roundtripping transactions with related parties; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were the materially misleading and/or lacked a reasonable basis.
If you suffered a loss in IonQ you have until August 1, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SPRO class action lawsuit has been filed on behalf of investors who purchased Spero Therapeutics, Inc. (SPRO) securities between October 28, 2021, and May 2, 2022. For more on the SPRO Lawsuit please contact us today.
According to the Spero Therapeutics lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(i) the data submitted in support of the New Drug Application (“NDA”) for the Company’s product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration (“FDA”); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero’s operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Spero Therapeutics you have until July 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CDNA class action lawsuit has been filed on behalf of investors who purchased CareDx, Inc. (CDNA) securities between February 24, 2021, and May 5, 2022. For more on the CDNA Lawsuit please contact us today.
According to the CareDx lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the Company’s RemoTraC service for remote, home-based, blood-drawing; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company’s testing services revenue reported throughout the class period artificially inflated; and (4) as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in CareDx you have until July 22, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an OKTA class action lawsuit has been filed on behalf of investors who purchased Okta, Inc.(OKTA) securities between March 5, 2021, and March 22, 2022. For more on the OKTA Lawsuit please contact us today.
According to the Okta lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Okta had inadequate cybersecurity controls; (ii) as a result, Okta’s systems were vulnerable to data breaches; (iii) Okta ultimately did experience a data breach caused by a hacking group, which potentially affected hundreds of Okta customers; (iv) Okta initially did not disclose and subsequently downplayed the severity of the data breach; (v) all the foregoing, once revealed, was likely to have a material negative impact on Okta’s business, financial condition, and reputation; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Okta you have until July 19, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a PEGA class action lawsuit has been filed on behalf of investors who purchased Pegasystems Inc. (PEGA) securities between May 29, 2020, and May 9, 2022 For more on the PEGA Lawsuit please contact us today.
According to the PEGA lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) PEGA had engaged in corporate espionage and misappropriation of trade secrets to better compete against Appian, a principal competitor; (2) defendants’ product development and associated success was, in significant part, not the result of its own research and product testing but rather the result of such corporate espionage and trade secret theft; (3) defendants had engaged in a scheme to steal Appian trade secrets, which was not only known to, but carried out through, the personal involvement of the Company’s CEO; (4) the Company’s CEO and other officers and employees did not comply with the Company’s written Code of Conduct, including its express prohibition on “stealing” confidential information from a competitor and “misrepresenting your identity in hopes of obtaining confidential information”; (5) the Company was “unable to reasonably estimate damages” in the lawsuit filed by Appian as a result of the foregoing misconduct (the “Appian Litigation”); and (6) as a result of the foregoing, defendants’ statements about PEGA’s business, operations, prospects, legal compliance, and potential damages exposure in the Appian Litigation were materially false and/or misleading and/or lacked a reasonable basis when made.
If you suffered a loss in PEGA you have until July 18, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AXSM class action lawsuit has been filed on behalf of investors who purchased Axsome Therapeutics, Inc.(AXSM) securities between December 30, 2019, and April 22, 2022. For more on the AXSM Lawsuit please contact us today.
According to the Axsome lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Axsome’s chemistry, manufacturing, and control (“CMC”) practices were deficient with respect to AXS-07, the Company’s medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application (“NDA”) on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration (“FDA”) reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Axsome you have until July 12, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a UPST class action lawsuit has been filed on behalf of investors who purchased Upstart, Inc. (UPST) securities between November 9, 2021, and May 9, 2022. For more on the UPST Lawsuit please contact us today.
According to the Upstart lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(1) Upstart’s AI model could not adequately account for macroeconomic factors such as interest rates that impact the market-clearing price for loans; (2) as a result, Upstart was experiencing a negative impact on its conversion rate; (3) as a result, the Company was reasonably likely to use its balance sheet to fund loans; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
If you suffered a loss in Upstart you have until July 12, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an OSCR class action lawsuit has been filed on behalf of investors who purchased Oscar Health, Inc. (OSCR) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Oscar Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s March 2021 initial public offering. For more on the OSCR Lawsuit please contact us today.
According to the Oscar lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Oscar was experiencing growing COVID-19 testing and treatment costs; (2) Oscar was experiencing growing net COVID costs; (3) Oscar would be negatively impacted by an unfavourable prior-year Risk Adjustment Data Validation result relating to 2019 and 2020; (4) Oscar was on track to be negatively impacted by significant SEP membership growth; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Oscar you have until July 11, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AMZN class action lawsuit has been filed on behalf of investors who purchased Amazon.com, Inc. (AMZN) securities between February 1, 2019, and April 5, 2022 For more on the AMZN Lawsuit please contact us today.
According to the Amazon lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Amazon engaged in anticompetitive conduct in its private-label business practices, including giving Amazon products preference over those of its competitors and using third-party sellers’ non-public data to compete with them; (ii) the foregoing exposed Amazon to a heightened risk of regulatory scrutiny and/or enforcement actions; (iii) Amazon’s revenues derived from its private-label business were in part the product of impermissible conduct and thus unsustainable; and (iv) as a result, the defendants’ public statements throughout the class period were materially false and/or misleading.
If you suffered a loss in Amazon you have until July 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a MULN class action lawsuit has been filed on behalf of investors who purchased Mullen Automotive, Inc. f/k/a Net Element, Inc. (MULN) securities between June 15, 2020, and April 6, 2022. For more on the MULN Lawsuit please contact us today.
According to the Mullen Automotive, Inc. f/k/a Net Element, Inc. or the “Company lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Mullen overstates its ability and timeline regarding production; (2) Mullen overstates its deals with business partners, including Qiantu; (3) Mullen overstates its battery technology and capabilities; (4) Mullen overstates its ability to sell its branded products; (5) Net Element did not conduct proper due diligence into Mullen Technologies; (6) the Dragonfly K50, a luxury sports car, was not (solely) delayed due to the COVID-19 pandemic; and (7) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in Mullen Automotive, Inc. f/k/a Net Element, Inc. or the “Company you have until July 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ARQQ class action lawsuit has been filed on behalf of investors who purchased Arqit Quantum Inc. f/k/a Centricus Acquisition Corp. (ARQQ) This lawsuit is on behalf of: (i) all persons or entities who purchased or otherwise acquired Arqit securities between September 7, 2021, and April 18, 2022, inclusive (the “Class Period”); and/or (ii) all holders of Centricus securities as of the record date for the special meeting of shareholders held on August 31, 2021, to consider approval of the merger between Arqit and Centricus (the “Merger”) and entitled to vote on the Merger. For more on the ARQQ Lawsuit please contact us today.
According to the Arqit Quantum Inc. f/k/a Centricus Acquisition Corp. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Arqit’s proposed encryption technology would require widespread adoption of new protocols and standards for telecommunications; (2) British cybersecurity officials questioned the viability of Arqit’s proposed encryption technology in a meeting in 2020; (3) the British government was not an Arqit customer but, rather, providing grants to Arqit; (4) Arqit had little more than an early-stage prototype of its encryption system at the time of the Merger; and (5) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Arqit Quantum Inc. f/k/a Centricus Acquisition Corp. you have until July 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an RSKD class action lawsuit has been filed on behalf of investors who purchased Riskified Ltd. (RSKD) The lawsuit seeks to recover losses on behalf of Riskified Ltd. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities who purchased Riskified Class A ordinary shares in or traceable to the Company’s July 2021 initial public offering Follow the link below to get more information and be contacted by a member of our team for more on the RSKD Lawsuit please contact us today.
According to the Riskified lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) as Riskified expanded its user base, the quality of Riskified’s machine learning platform had deteriorated (rather than improved as represented in documents issued in connection with the July 2021 initial public offering), because of, among other things, inaccuracies in the algorithms associated with onboarding new merchants and entering new geographies and industries; (ii) Riskified had expanded its customer base into industries with relatively high rates of fraud – including partnerships with cryptocurrency and remittance business – in which Riskified had limited experience and that this expansion has negatively impacted the effectiveness of Riskified’s machine learning platform; (iii) as a result, Riskified was suffering from materially higher chargebacks and cost of revenue and depressed gross profits and gross profit margins during its third fiscal quarter of 2021; and (iv) thus, the representations in documents issued in connection with the July 2021 initial public offering regarding Riskified’s historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of Riskified prior to and at the time of the July 2021 initial public offering, and were materially false and misleading, and lacked a factual basis.
If you suffered a loss in Riskified you have until July 1, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an NFLX class action lawsuit has been filed on behalf of investors who purchased Netflix, Inc.(NFLX) securities between October 19, 2021, and April 19, 2022 For more on the NFLX Lawsuit please contact us today.
According to the Netflix lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Netflix was exhibiting slower acquisition growth due to, among other things, account sharing by customers and increased competition from other streaming services; (2) the Company was experiencing difficulties retaining customers; (3) as a result of the foregoing, the Company was losing subscribers on a net basis (4) as a result, the Company’s financial results were being adversely affected; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
If you suffered a loss in Netflix you have until July 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an IIPR class action lawsuit has been filed on behalf of investors who purchased Innovative Industrial Properties, Inc. (IIPR) securities between May 7, 2020, and April 13, 2022. For more on the IIPR Lawsuit please contact us today.
According to the Innovative Industrial Properties lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Innovative Industrial Properties’ focus is to be a cannabis company lender rather than a REIT; (2) that the true values of the Company’s properties are significantly lower than Innovative Industrial Properties represents; (3) there are existential issues in its top customers; (4) as a result, its top customers may not be able to continue making payments to Innovative Industrial Properties and the Company would face significant issues replacing these customers; and (5) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Innovative Industrial Properties you have until June 24, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an NTRA class action lawsuit has been filed on behalf of investors who purchased Natera, Inc. (NTRA) securities between February 26, 2020, and April 19, 2022. For more on the NTRA Lawsuit please contact us today.
According to the Natera lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company’s screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants’ false and misleading claims about Natera’s technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.
If you suffered a loss in Natera you have until June 27, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an IRNT class action lawsuit has been filed on behalf of investors who purchased Ironnet, Inc.(IRNT) securities between September 15, 2021, and December 15, 2021. For more on the IRNT Lawsuit please contact us today.
According to the Ironnet lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company had materially overstated its business and financial prospects; (ii) the Company was unable to predict the timing of significant customer opportunities which constituted a substantial portion of its publicly- issued FY 2022 financial guidance; (iii) the Company had not established effective disclosure controls and procedures to reasonably ensure its public disclosures were timely, accurate, complete, and not otherwise misleading; and (iv) as a result, the Company’s public statements were materially false, misleading, and/or lacked any reasonable basis in fact at all relevant times.
If you suffered a loss in Ironnet you have until June 21, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a BKKT class action lawsuit has been filed on behalf of investors who purchased Bakkt Holdings, Inc. f/k/a VPC Impact Acquisition Holdings (BKKT) (a) Bakkt securities between March 31, 2021, and November 19, 2021, both dates inclusive; and/or (b) Bakkt Class A common stock pursuant and/or traceable to documents issued in connection with the business combination between the Company and Bakkt Holdings, LLC completed on or about October 15, 2021. For more on the BKKT Lawsuit please contact us today.
According to the Bakkt Holdings lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company had defective financial controls; (ii) as a result, there were errors in the Company’s financial statements related to the misclassification of certain shares issued prior to the business combination between the Company and Bakkt Holdings, LLC; (iii) accordingly, the Company would need to restate certain of its financial statements; (iv) the Company downplayed the true scope and severity of these issues; (v) the Company overstated the remediation of its defective financial controls; and (vi) as a result, the documents issued in connection with the business combination and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
If you suffered a loss in Bakkt Holdings you have until June 20, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a LICY class action lawsuit has been filed on behalf of investors who purchased Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. (LICY) securities between February 16, 2021, and March 23, 2022. For more on the LICY Lawsuit please contact us today.
According to the Li-Cyclelawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Li-Cycle’s largest customer, Traxys, is not actually a customer, but merely a broker providing working capital financial to the Company while Traxys tries to sell Li-Cycle’s product to end customers; (2) the Company engaged in highly questionable related party transactions; (3) the Company’s mark-to-model accounting is vulnerable to abuse and gave a false impression of growth; (4) a significant portion of the Company’s reported revenues were derived from simply marking up receivables on products that had not been sold; (5) the Company’s gross margins have likely been negative since inception; (6) the Company will require an additional $1 billion of funding to support its planned growth (which is a figure greater than the Company raised via the merger); and (7) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in Li-Cycle you have until June 20, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a LILM class action lawsuit has been filed on behalf of investors who purchased Lilium N.V. f/k/a Qell Acquisition Corp. (LILM) securities between March 30, 2021, and March 14, 2022. For more on the LILM Lawsuit please contact us today.
According to the Lilium N.V. f/k/a Qell Acquisition Corp lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Lilium materially overstates the design and capabilities of the Lilium Jet, an electric vertical take-off-and-landing aircraft for use in a new type of high-speed air transport system for people and goods; (2) Lilium materially overstates the likelihood for the Lilium Jet’s timely certification; (3) Lilium misrepresents its ability to obtain or create the necessary batteries for the Lilium Jet; (4) the special purpose acquisition company merger would not and did not generate enough cash to commercially launch the Lilium Jet; (5) Qell Acquisition Corp. did not engage in proper due diligence regarding its merger with Lilium GmbH; and (6) as a result, Defendants’ public statements and statements to journalists were materially false and/or misleading at all relevant times.
If you suffered a loss in Lilium N.V. f/k/a Qell Acquisition Corp you have until June 17, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AUPH class action lawsuit has been filed on behalf of investors who purchased Aurinia Pharmaceuticals Inc. (AUPH) securities between May 7, 2021, and February 25, 2022. For more on the AUPH Lawsuit please contact us today.
According to the Aurinia Pharmaceuticalslawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia’s 2022 sales outlook for the Company’s only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS’s commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aurinia Pharmaceuticals you have until June 14, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SDIG class action lawsuit has been filed on behalf of investors who purchased Stronghold Digital Mining, Inc. (SDIG) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Stronghold Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s October 2021 initial public offering. For more on the SDIG Lawsuit please contact us today.
According to the Stronghold Digital Mininglawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) contracted suppliers, including Minerva Semiconductor Corp., were reasonably likely to miss anticipated delivery quantities and deadlines; (2) due to strong demand and pre-sold supply of mining equipment in the industry, Stronghold would experience difficulties obtaining miners outside of confirmed purchase orders; (3) as a result of the foregoing, there was a significant risk that Stronghold could not expand its mining capacity as expected; (4) as a result, Stronghold would likely experience significant losses; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Stronghold Digital Mining you have until June 13, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a MYPS class action lawsuit has been filed on behalf of investors who purchased Playstudios, Inc. (MYPS) (a) purchased, or otherwise acquired securities of Playstudios between June 22, 2021, and March 1, 2022, both dates inclusive, including, but not limited to, those who purchased or acquired Playstudios securities pursuant to the offering of the private investment in public equity (“PIPE” offering); (b) held common stock of Acies as of May 25, 2021, and were eligible to vote at Acies’ June 16, 2021, special meeting who exchanged their shares of Acies stock for shares of Playstudios stock pursuant to the merger of Acies and Old Playstudios (the “Merger”); and/or (c) purchased or otherwise acquired Playstudios common stock pursuant to or traceable to Acies’ documents issued in connection with the June 2021 Merger. For more on the MYPS Lawsuit please contact us today.
According to the Playstudios lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Playstudios was having significant problems with its flagship game, Kingdom Boss; (ii) Playstudios would not be releasing Kingdom Boss as expected; and (iii) Playstudios had not revised its financial projections to account for the problems it had encountered with Kingdom Boss. As a result of the defendants’ wrongful conduct, Class members paid artificially inflated prices for their Playstudios securities and suffered substantial losses and damages.
If you suffered a loss in Playstudios you have until June 6, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an IBM class action lawsuit has been filed on behalf of investors who purchased International Business Machines Corporation (IBM) securities between April 4, 2017, and October 20, 2021. For more on the IBM Lawsuit please contact us today.
According to the IBM lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Strategic Imperatives Revenue and growth, CAMSS and CAMSS Components’ revenue and growth, and the Company’s Segments’ revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (ii) the Company’s present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue and, as a result (iii) the Company misled the market by portraying the Company’s Strategic Imperative’s financial performance and future prospects more favorable than they actually were as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives.
If you suffered a loss in IBM you have until June 6, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ABBV class action lawsuit has been filed on behalf of investors who purchased AbbVie Inc. (ABBV) securities between April 30, 2021, and August 31 2021. For more on the ABBV Lawsuit please contact us today.
According to the AbbVie lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.’s drug Xeljanz extended to Abbvie’s drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
If you suffered a loss in AbbVie you have until June 6, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an LCID class action lawsuit has been filed on behalf of investors who purchased Lucid Group, Inc. (LCID) securities between November 15, 2021, and February 28, 2022. For more on the LCID Lawsuit please contact us today.
According to the Lucid Grouplawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: The filed complaint alleges that defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Lucid’s business and operations. Specifically, the Company overstated its production capabilities while concealing that “extraordinary supply chain and logistics challenges” were hampering Lucid’s operations. As a result of the defendants’ wrongful acts and omissions, and the significant decline in the market value of Lucid’s common stock, Lucid investors have suffered significant damages.
If you suffered a loss in Lucid Group you have until May 31, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a VLTA class action lawsuit has been filed on behalf of investors who purchased Volta Inc. (VLTA) securities between August 2, 2021, and March 28, 2022. For more on the VLTA Lawsuit please contact us today.
According to the Voltalawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Volta had improperly accounted for restricted stock units issued in connection with the business combination of Volta Industries, Inc. (“Legacy Volta”) and Tortoise Acquisition Corp. II; (2) as a result, the Company had understated its net loss for third-quarter 2021; (3) there were material weaknesses in the Company’s internal control over financial reporting that resulted in a material error; (4) as a result of the foregoing, the Company would restate its financial statements; (5) as a result of the foregoing, Legacy Volta’s founders would imminently exit the Company; (6) as a result, the Company’s financial results would be adversely impacted; and (7) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Volta you have until May 31, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a FIXX class action lawsuit has been filed on behalf of investors who purchased Homology Medicines, Inc. (FIXX) securities between June 10, 2019, and February 18, 2022 For more on the FIXX Lawsuit please contact us today.
According to the Homologylawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Homology you have until May 24, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a VRT class action lawsuit has been filed on behalf of investors who purchased Vertiv Holdings Co (VRT) securities between April 28, 2021, and February 23, 2022 For more on the VRT Lawsuit please contact us today.
According to the Vertivlawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company could not adequately respond to supply chain issues and inflation by increasing its prices; (2) as a result of the increasing costs, Vertiv’s earnings would be adversely impacted; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Vertiv you have until May 23, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a GRAB class action lawsuit has been filed on behalf of investors who purchased Grab Holdings Limited (GRAB) securities between November 12, 2021, and March 2, 2022. For more on the GRAB Lawsuit please contact us today.
According to the Grab Holdings lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Grab’s driver supply declined during the third quarter; (2) as a result, Grab continued to invest heavily in driver and consumer incentives to “preemptively recalibrate driver supply”; (3) as a result, the Company’s financial results would be adversely impacted, including, among other things, a significant decline in revenue; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Grab Holdings you have until May 16, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CELH class action lawsuit has been filed on behalf of investors who purchased Celsius Holdings, Inc.(CELH) securities between August 12, 2021, and March 1, 2022. For more on the CELH Lawsuit please contact us today.
According to the Celsiuslawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had improperly recorded expenses for non-cash share-based compensation for the second and third quarters of 2021; (2) as a result, the Company’s financial statements for those periods would be restated, including to report a net loss for the third quarter of 2021; (3) there was a material weakness in Celsius’s internal controls over financial reporting; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Celsius you have until May 16, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a FB class action lawsuit has been filed on behalf of investors who purchased Meta Platforms, Inc. (FB) securities between March 2, 2021, and February 2, 2022. For more on the FB Lawsuit please contact us today.
According to the Meta Platformslawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Apple’s iOS privacy changes were having a material impact on Meta’s ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta’s mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
If you suffered a loss in Meta Platforms you have until May 9, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AKBA class action lawsuit has been filed on behalf of investors who purchased Akebia Therapeutics, Inc. (AKBA) securities between June 28, 2018, and September 2, 2020 For more on the AKBA Lawsuit please contact us today.
According to the Akebialawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anaemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Akebia you have until May 13, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AFRM class action lawsuit has been filed on behalf of investors who purchased Affirm Holdings, Inc.(AFRM) This lawsuit is on behalf of all investors who purchased or otherwise acquired Affirm Holdings, Inc. securities on February 10, 2022, after the Company sent a Tweet concerning its Second Quarter 2022 financial results at approximately 1:15 p.m. EST. For more on the AFRM Lawsuit please contact us today.
According to the Affirm Holdings lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint, on February 10, 2022, at approximately 1:15 p.m., Affirm issued a Tweet from its official account in which the Company disclosed certain metrics from its second-quarter 2022 financial results. The Tweet, which was published prior to the Company’s planned release of its financial results, portrayed a highly successful quarter, which included an increase in revenue of 77%. This caused Affirm’s share price to spike nearly 10% in intra-day trading. The Tweet was materially misleading, in that it omitted to disclose the full details of Affirm’s second-quarter financial results. Affirm deleted the Tweet and released its full second-quarter financial results ahead of schedule. The full financial results were lacklustre – with the Company posting a loss of $0.57 per share, compared with analyst expectations of $0.37 per share.
If you suffered a loss in Affirm Holdings you have until April 29, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ERIC class action lawsuit has been filed on behalf of investors who purchased Telefonaktiebolaget LM Ericsson NEWS (ERIC) securities between April 27, 2017, and February 25, 2022 For more on the ERIC Lawsuit please contact us today.
According to the Telefonaktiebolaget LM Ericsson lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Ericsson overstated the extent to which it had reformed its business practices to eliminate the use of bribes to secure business in foreign countries; (ii) Ericsson had paid bribes to the terrorist group the Islamic State in Iraq and Syria to gain access to certain transport routes in Iraq; (iii) accordingly, the Company’s revenues derived from its operations in Iraq were, in at least substantial part, derived from unlawful conduct and thus unsustainable; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Telefonaktiebolaget LM Ericsson you have until May 2, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AI class action lawsuit has been filed on behalf of investors who purchased C3.ai, Inc. (AI) (a) C3.ai Class A common stock pursuant and/or traceable to the documents issued in connection with the Company’s initial public offering conducted on or about December 9, 2020; and/or (b) C3.ai securities between December 9, 2020, and February 15, 2022, both dates inclusive. For more on the AI Lawsuit please contact us today.
According to the C3.ai lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) C3.ai’s partnership with Baker Hughes was deteriorating; (ii) C3.ai was employing a flawed accounting methodology to conceal the deterioration of its Baker Hughes partnership; (iii) C3.ai faced challenges in product adoption and significant salesforce turnover; (iv) the Company overstated, inter alia, the extent of its investment in technology, description of its customers, its total addressable market, the pace of its market growth, and the scale of alliances with its major business partners; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in C3.ai you have until May 3, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a RIVN class action lawsuit has been filed on behalf of investors who purchased Rivian Automotive, Inc. (RIVN) This lawsuit is on behalf of investors that purchased or otherwise acquired Rivian common stock pursuant and/or traceable to Rivian’s Initial Public Offering on November 10, 2021. For more on the RIVN Lawsuit please contact us today.
According to the Rivian Automotive lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: The Registration Statement (documents issued in connection with the initial public offering) contained representations that were materially inaccurate, misleading, and/or incomplete because they failed to disclose, among other things, that the R1T electric pickup truck and R1S electric SUV were underpriced to such a degree that Rivian would have to raise prices shortly after the IPO and that these price increases would tarnish Rivian’s reputation as a trustworthy and transparent company and would put a significant number of the existing backlog of 55,400 preorders, along with future preorders, in jeopardy of cancellation.
If you suffered a loss in Rivian Automotive you have until May 6, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CABA class action lawsuit has been filed on behalf of investors who purchased Cabaletta Bio, Inc. (CABA) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019, and December 13, 2021, For more on the CABA Lawsuit please contact us today.
According to the Cabaletta lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta’s lead product candidate, DSG3-CAART, had, among other things, worsened certain participants’ disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cabaletta you have until April 29, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a SO class action lawsuit has been filed on behalf of investors who purchased The Southern Company (SO) securities between May 10, 2013, and February 20, 2020 For more on the SO Lawsuit please contact us today.
According to the Southern lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint, Deloitte & Touche, LLP allegedly made false and/or materially misleading statements in connection with its audit of The Southern Company’s financial statements and, in particular, its “clean coal” electric power plant in Kemper, Mississippi. Between May 10, 2013 and February 20, 2020 (the “Class Period”), Deloitte intentionally and recklessly violated its professional responsibilities as Southern’s professional auditor and deceived investors about Southern’s accounting for and expected completion of the Kemper Plant. Deloitte’s untrue statements and omissions of material facts concerning the Kemper Plant operated as a fraud and deceit upon plaintiff and others similarly situated in connection with their purchases and value of Southern securities during the Class Period.
If you suffered a loss in Southern you have until April 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CRNC class action lawsuit has been filed on behalf of investors who purchased Cerence Inc. (CRNC) securities between February 8, 2021, and February 4, 2022. For more on the CRNC Lawsuit please contact us today.
According to the Cerence lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the global semiconductor shortage had a materially negative impact on demand for Cerence’s software licenses; (2) defendants masked the impact of the semiconductor shortage on demand for the Company’s software licenses by pulling forward sales; and (3) as a result of the above, defendants’ statements about Cerence’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Cerence you have until April 26, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TASK class action lawsuit has been filed on behalf of investors who purchased Taskus, Inc.(TASK) securities between June 11, 2021, and January 19, 2022. For more on the TASK Lawsuit please contact us today.
According to the Taskus lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) TaskUs was experiencing severe financial strain and business challenges, particularly with its most important customer, Facebook; (2) the Content Security market was smaller than defendants represented and defendants’ representations were based on outdated market data; (3) TaskUs improperly recognized revenue from certain key contracts; (4) defendants overstated the size of TaskUs’ workforce as well as employee retention rates, and understated attrition rates; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Taskus you have until April 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a GATO class action lawsuit has been filed on behalf of investors who purchased Gatos Silver, Inc. (GATO) This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Gatos: (a) common stock pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about October 28, 2020; and/or (b) securities between October 28, 2020, and January 25, 2022, For more on the GATO Lawsuit please contact us today.
According to the Gatos lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the technical report for Gatos’s primary mine, the Cerro Los Gatos deposit, contained certain errors; (2) among other things, the mineral reserves had been overestimated by as much as 50%; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Gatos you have until April 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an MP class action lawsuit has been filed on behalf of investors who purchased MP Materials Corp. f/k/a Fortress Value Acquisition Corp. (MP) securities between May 1, 2020, and February 2, 2022 For more on the MP Lawsuit please contact us today.
According to the MP Materials Corp lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Fortress Value Acquisition Corp. (“FVAC”) had overstated its due diligence efforts and expertise with respect to identifying target companies to acquire; (ii) FVAC performed inadequate due diligence into Legacy MP Materials prior to the business combination, or else ignored significant red flags regarding, inter alia, Legacy MP Materials’ management, compliance policies, and Mountain Pass’s profitability; (iii) as a result, the Company’s future business and financial prospects post-business combination were overstated; (iv) MP Materials engaged in an abusive transfer price manipulation scheme with a related party in the People’s Republic of China to artificially inflate the Company’s profits; (v) MP Materials’ ore at the Mountain Pass Rare Earth Mine and Processing Facility was not economically viable to harvest for rare earth metals; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in MP Materials Corp you have until April 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SPWR class action lawsuit has been filed on behalf of investors who purchased SunPower Corporation (SPWR) securities between August 3, 2021, and January 20, 2022. For more on the SPWR Lawsuit please contact us today.
According to the SunPower Corporation lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) certain connectors used by SunPower suffered from cracking issues; (2) as a result, the Company was reasonably likely to incur costs to remediate the faulty connectors; (3) as a result of the foregoing, SunPower’s financial results would be adversely impacted; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in SunPower Corporation you have until April 18, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a BFLY class action lawsuit has been filed on behalf of investors who purchased Butterfly Network, Inc. f/k/a Longview Acquisition Corp. (BFLY) (a) all persons or entities that purchased or otherwise acquired Butterfly securities between February 16, 2021, and November 15, 2021, both dates inclusive and/or (b) all holders of Butterfly common stock as of the record date for the special meeting of shareholders held on February 12, 2021, to consider approval of the merger between Longview Acquisition Corp. and Butterfly. securities between February 16, 2021, and November 15, 2021. For more on the BFLY Lawsuit please contact us today.
According to the Butterfly Network lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Butterfly had overstated its post-merger business and financial prospects; (ii) notwithstanding the ongoing COVID-19 pandemic, Butterfly’s financial projections failed to take into account the pandemic’s broad consequences, which included healthcare logistical challenges, and medical personnel fatigue; (iii) accordingly, Butterfly’s gross margin levels and revenue projections were less sustainable than the Company had represented; (iv) all the foregoing was reasonably likely to have a material negative impact on Butterfly’s business and financial condition; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Butterfly Network you have until April 18, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an AFIB class action lawsuit has been filed on behalf of investors who purchased Acutus Medical, Inc. (AFIB) securities between May 13, 2021, and November 11, 2021, For more on the AFIB Lawsuit please contact us today.
According to the AcQMap lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) a material percentage of the Company’s AcQMap imaging and mapping systems under evaluation had been randomly installed at sites with little, if any, consideration given to whether the healthcare providers at the selected locations were likely to adopt, or desire, the Company’s products; (b) a material percentage of the AcQMap systems under evaluation had been installed in locations where the Company did not possess the infrastructure necessary to appropriately educate, train, and support medical service providers on the system’s operations; (c) as a result of (a) and (b) above, defendants were in the process of designing a strategic plan to terminate and relocate approximately 20% of then-existing AcQMap systems evaluation arrangements; (d) the Company’s management discussion and analysis was materially false and misleading and failed to disclose that the termination and relocation of approximately 20% of existing AcQMap systems evaluation arrangements was reasonably likely to have a material adverse effect on the Company’s 2021 financial results; and (e) the Company’s risk factor discussions were materially false and misleading and made reference to potential risks without disclosing that such risks were then-existing or adequately describing the specific nature of the risks then facing the Company.
If you suffered a loss in AcQMap you have until April 18, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ASTR class action lawsuit has been filed on behalf of investors who purchased Astra Space Inc. f/k/a Holicity Inc. (ASTR) securities between February 2, 2021, and December 29, 2021. For more on the ASTR Lawsuit please contact us today.
According to the Astra Space Inc. f/k/a Holicity lawsuit, throughout the Class Period defendants, made false and/or misleading statements and/or failed to disclose that: (1) Astra cannot launch “anywhere”; (2) Astra significantly overstated its addressable market; (3) Astra overstated the effectiveness of its designs and reliability; (4) Astra significantly overstated its plans for diversification and its broadband constellation plan; and (5) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in Astra Space Inc. f/k/a Holicity you have until April 11, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a FENC class action lawsuit has been filed on behalf of investors who purchased Fennec Pharmaceuticals Inc. (FENC) securities between May 28, 2021, and November 26, 2021. For more on the FENC Lawsuit please contact us today.
According to the Fennec Pharmaceuticals lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Fennec Pharmaceuticals you have until April 11, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a BIIB class action lawsuit has been filed on behalf of investors who purchased Biogen Inc. (BIIB) securities between June 7, 2021, and January 11, 2022. For more on the BIIB Lawsuit please contact us today.
According to the Biogen lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: 1) there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration (“FDA”) that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer’s disease; 2) the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer’s patients; 3) ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019, and 4) defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and those side-effects were dangerous and serious.
If you suffered a loss in Biogen you have until April 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TLS class action lawsuit has been filed on behalf of investors who purchased Telos Corporation (TLS) securities between November 19, 2020, and November 12, 2021 For more on the TLS Lawsuit please contact us today.
According to the Telos Corporation lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Transportation Security Administration (“TSA”) and Centers for Medicare and Medicaid Services (“CMS”) contracts, which constituted a majority of the Company’s future revenues, were not on track to commence as represented at the end of 2021 and in 2022; (2) Defendants lacked a reasonable basis and sufficient visibility to provide and affirm the Company’s 2021 guidance in the face of the uncertainty surrounding the TSA and CMS contracts; (3) COVID-19- and hacking scandal-related headwinds were throwing off the timing for performance of the TSA and CMS contracts and their associated revenues; (4) as a result, the guidance provided by Defendants was not in fact “conservative”; (5) as a result of the delays, Telos would be forced to dramatically reduce its revenue estimates; and (6) as a result of the foregoing, Defendants’ statements about Telos’ business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
If you suffered a loss in Telos Corporation you have until April 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TAL class action lawsuit has been filed on behalf of investors who purchased Tal Education Group (TAL) securities between April 26, 2018, and July 22, 2021. For more on the TAL Lawsuit please contact us today.
According to the TAL lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) TAL’s revenue and operational growth was the result of deceptive marketing tactics and illicit business practices that flouted Chinese laws, regulations and policies, and exposed the Company to an extreme risk that more draconian measures would be imposed on the Company; (b) TAL had engaged in misleading and fraudulent advertising practices, including the provision of false and misleading discount information designed to obfuscate the true cost of the Company’s programs to its customers, the creation of fake customer reviews designed to fraudulently lure new customers to TAL programs, the misrepresentation of teacher qualifications and course qualities, and the marketing of rigged promotional events; (c) TAL had defied Chinese policies designed to alleviate the burden imposed by tutoring services on students and their families, including by imposing hefty advances and recurring debt payments on course enrollees, by offering courses designed to give affluent students unfair advantages, by holding courses outside of allowable tutoring hours, and by linking for-profit courses to government-mandated schooling; (d) as a result of the foregoing, TAL was subject to an extreme undisclosed risk of adverse enforcement actions, regulatory fines and penalties, and the imposition of new rules and regulations adverse to the Company’s business and financial interests; and (e) as a result of the foregoing, TAL’s historical growth was not sustainable or the result of legitimate business tactics as represented, and defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and lacked a reasonable factual basis.
If you suffered a loss in TAL you have until April 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an EDU class action lawsuit has been filed on behalf of investors who purchased New Oriental Education & Technology Group Inc. (EDU) securities between April 24, 2018, and July 22, 2021. For more on the EDU Lawsuit please contact us today.
According to the New Oriental lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) New Oriental’s revenue and operational growth was the result of deceptive marketing tactics and abusive business practices that flouted Chinese regulations and policies and exposed the Company to an extreme risk that more draconian measures would be imposed on the Company; (b) New Oriental had engaged in misleading and fraudulent advertising practices, including the provision of false and misleading discount Information designed to obfuscate the true cost of the Company’s programs to its customers; (c) New Oriental had falsified teacher qualifications and experience in order to attract customers and increase student enrollments; (d) New Oriental had defied prior government warnings against linking school enrollments with the provision of private tutoring services; (e) as a result of the foregoing, New Oriental was subject to an extreme undisclosed risk of adverse enforcement actions, regulatory fines and penalties, and the imposition of new rules and regulations adverse to the Company’s business and interests; and (f) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and lacked a reasonable, factual basis.
If you suffered a loss in New Oriental you have until April 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ELMS class action lawsuit has been filed on behalf of investors who purchased Electric Last Mile Solutions, Inc. f/k/a Forum Merger III Corp. (ELMS) securities between March 31, 2021, and February 1, 2022. For more on the ELMS Lawsuit please contact us today.
According to the ELMS lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) ELMS’ previously issued financial statements were false and unreliable; (2) ELMS’s earlier reported financial statements would need restatement; (3) certain ELMS executives and/or directors purchased equity in the Company at substantial discounts to market value without obtaining an independent valuation; (4) on November 25, 2021 (Thanksgiving), the Company’s Board formed an independent Special Committee to conduct an inquiry into certain sales of equity securities made by and to individuals associated with the Company; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in ELMS you have until April 4, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an STTK class action lawsuit has been filed on behalf of investors who purchased Shattuck Labs, Inc. (STTK) This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Shattuck securities: (1) pursuant and/or traceable to the registration statement and related prospectus issued in connection with Shattuck’s October 2020 initial public offering; and/or (2) between October 9, 2020, and November 9, 2021, For more on the STTK Lawsuit please contact us today.
According to the Shattuck lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the collaboration agreement with Takeda was not solid; (2) Takeda and Shattuck would “mutually agree” to terminate the collaboration agreement in essentially one year; (3) as a result, Shattuck would cease to receive any future milestone, royalty, or other payments from Takeda; and (4) as a result, defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Shattuck you have until April 1, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TALK class action lawsuit has been filed on behalf of investors who purchased Talkspace, Inc. f/k/a Hudson Executive Investment Corporation (TALK) The lawsuit seeks to recover losses on behalf of Talkspace investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of: (a) all persons or entities that purchased or otherwise acquired Talkspace securities between June 11, 2020 and November 15, 2021, both dates inclusive, and/or (b) all holders of Talkspace common stock as of the record date for the special meeting of shareholders held on June 17, 2021. For more on the TALK Lawsuit please contact us today.
According to the Talkspace lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Hudson Executive Investment Corporation (“HEIC”) had overstated its competitive advantage and due diligence capabilities with respect to identifying and effectuating a merger with target companies; (ii) HEIC had conducted inadequate due diligence into then-private, pre-Merger Talkspace, or else ignored and/or failed to disclose multiple red flags concerning then-private, pre-Merger Talkspace’s business and operations; (iii) Talkspace was experiencing significantly increased online advertising costs in its B2C business since the beginning of 2021; (iv) Talkspace was experiencing lower conversion rates in its online advertising in its business-to-consumer (“B2C”) business; (v) as a result of (iii) and (iv) above, Talkspace was experiencing increased customer acquisition costs and more tepid B2C demand than represented to investors; (vi) as a result of (iii)-(v) above, Talkspace was suffering from ballooning customer acquisition costs and worsening growth and gross margin trends; (vii) Talkspace had overvalued its accounts receivables from certain of its health plan clients in its B2B business, which amounts required adjustment downward; and (viii) as a result of (iii)-(vii) above, Talkspace’s 2021 financial guidance was not achievable and lacked any reasonable basis in fact.
If you suffered a loss in Talkspace you have until March 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SLI class action lawsuit has been filed on behalf of investors who purchased Standard Lithium Ltd. (SLI) securities between May 19, 2020, and November 17, 2021 For more on the SLI Lawsuit please contact us today.
According to the Standard Lithium lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the LiSTR Direct Lithium Extraction technology’s extraction recovery efficiencies were overstated; (ii) accordingly, the Company’s final product lithium recovery percentage at the Demonstration Plant would not be as high as the Company had represented to investors; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Standard Lithium you have until March 28, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a BMBL class action lawsuit has been filed on behalf of investors who purchased Bumble Inc. (BMBL) This lawsuit is on behalf of all purchasers of the Class A common stock of Bumble directly in Bumble’s secondary public stock offering which took place on or about September 10, 2021. For more on the BMBL Lawsuit please contact us today.
According to the Bumble lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) Bumble’s paying user growth trends had abruptly reversed in 3Q21 and the Company had actually lost tens of thousands of paying users during the quarter; (b) paying users had been more reluctant to sign up for the Bumble app during 3Q21 because of the recent price hike for paid services on the app; (c) a material number of paying users were leaving the Badoo app, a dating-focused social network, and/or could not make payments through the Badoo app due, in substantial part, to problems arising from the Company’s transition of its payment platform; and (d) as a result of the foregoing, Bumble’s business metrics and financial prospects were not as strong as the Registration Statement had represented.
If you suffered a loss in Bumble you have until March 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CLVT class action lawsuit has been filed on behalf of investors who purchased Clarivate Plc (CLVT) securities between February 26, 2021, and December 27, 2021. For more on the CLVT Lawsuit please contact us today.
According to the Clarivate lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Clarivate maintained defective disclosure controls and procedures as a result of a material weakness in its internal control over financial reporting; (ii) the foregoing material weakness was not limited to how the Company accounted for warrants; (iii) as a result, Clarivate failed to properly account for an equity plan included in its acquisition of CPA Global, a global leader in Intellectual Property software and tech-enabled services; (iv) accordingly, the Company was reasonably likely to restate one or more of its previously issued financial statements following its acquisition of CPA Global; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Clarivate you have until March 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an OSH class action lawsuit has been filed on behalf of investors who purchased Oak Street Health, Inc. (OSH) securities between August 6, 2020, and November 8, 2021. For more on the OSH Lawsuit please contact us today.
According to the Oak Street lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) that Oak Street maintained relationships with third-party marketing agents likely to provoke law enforcement scrutiny; (2) that Oak Street was providing free transportation to federal health care beneficiaries in a manner that would provoke law enforcement scrutiny; (3) that these activities may be violations of the False Claims Act; (4) that, as such, Oak Street was at heightened risk of investigation by the U.S. Department of Justice and/or other federal law enforcement agencies; (5) that, as a result, Oak Street was subject to adverse impacts related to defence and settlement costs and diversion of management resources; and (6) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Oak Street you have until March 14, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a TLIS class action lawsuit has been filed on behalf of investors who purchased Talis Biomedical Corporation (TLIS) common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 2021 initial public offering (“IPO”). You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. For more on the TLIS Lawsuit please contact us today.
According to the Talis lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis’s Emergency Use Authorization application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company’s commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Talis you have until March 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an FSLR class action lawsuit has been filed on behalf of investors who purchased First Solar, Inc. (FSLR) securities between February 22, 2019, and February 20, 2020. For more on the FSLR Lawsuit please contact us today.
According to the First Solar lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint, defendants made repeated misrepresentations to investors regarding the development of First Solar’s newest “Series 6” solar module, the cost per unit it could achieve with that module, and the impact the changeover to this new product would have on the viability of its other business segments. As a result of the defendants’ misrepresentations, First Solar common stock was traded at artificially inflated prices during the class period.
If you suffered a loss in First Solar you have until March 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a DISCA class action lawsuit has been filed on behalf of investors who purchased Discovery Inc. (DISCA) securities between March 22, 2021, and March 29, 2021 For more on the DISCA Lawsuit please contact us today.
According to the Discovery lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint: Goldman Sachs and Morgan Stanley sold a large amount of Discovery shares during the class period while in possession of material, non-public information about Archegos and its need to fully liquidate its position in the Company because of margin call pressure. As a result of these sales, Defendants Goldman Sachs and Morgan Stanley avoided billions in losses combined.
If you suffered a loss in Discovery you have until March 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an MMAT class action lawsuit has been filed on behalf of investors who purchased Meta Materials Inc. f/k/a Torchlight Energy Resources, Inc. (MMAT) securities between September 21, 2020, and December 14, 2021. For more on the MMAT Lawsuit please contact us today.
According to the Meta Materials lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the business combination would result in a U.S. Securities and Exchange Commission investigation and subpoena in the matter captioned In the matter of Torchlight Energy Resources, Inc.; (2) the Company has materially overstated its business connections and dealings; (3) the Company has materially overstated its ability to produce and commercialize its products; (4) the Company has materially overstated its products’ novelty and capabilities; (5) the Company’s products did not have the potential to be disruptive because, among other things, the Company priced its products too high; and (6) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in Meta Materials you have until March 4, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an INSD class action lawsuit has been filed on behalf of investors who purchased Instadose Pharma Corp. f/k/a Mikrocoze, Inc.(INSD) securities between December 8, 2020, and November 24, 2021. For more on the INSD Lawsuit please contact us today.
According to the Instadose lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Instadose had performed inadequate due diligence into the business combination and/or ignored significant red flags associated with Instadose Canada; (ii) Instadose’s internal controls and policies were inadequate to detect and/or prevent impermissible trading activity by control persons of the Company; (iii) the foregoing subjected Instadose to a heightened risk of regulatory scrutiny and enforcement action; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Instadose you have until February 28, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a BHG class action lawsuit has been filed on behalf of investors who purchased Bright Health Group, Inc. (BHG) (a) common stock pursuant and/or traceable to the documents issued in connection with the Company’s initial public offering conducted on or about June 24, 2021; and/or (b) securities between June 24, 2021, and November 10, 2021. For more on the BHG Lawsuit please contact us today.
According to the Bright Health lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Bright Health had overstated its post-IPO business and financial prospects; (ii) the Company was ill-equipped to handle the impact of COVID-19-related costs; (iii) the Company was experiencing a decline in premium revenue because of a failure to capture risk adjustment on newly added lives; (iv) all the foregoing was reasonably likely to have a material negative impact on Bright Health’s business and financial condition; and (v) as a result, the documents issued in connection with the IPO and Defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
If you suffered a loss in Bright Health you have until March 7, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a DOCU class action lawsuit has been filed on behalf of investors who purchased Docusign, Inc. (DOCU) securities between March 27, 2020, and December 2, 2021. For more on the DOCU Lawsuit please contact us today.
According to the Docusign lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the impact of the Covid-19 pandemic on DocuSign’s business was positive, not negative; (2) DocuSign misrepresented the role that the Covid-19 pandemic had on its growth; (3) DocuSign downplayed the impact that a ‘return to normal’ would have on the Company’s growth and business; and (4) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in Docusign you have until February 22, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a CHGG class action lawsuit has been filed on behalf of investors who purchased Chegg, Inc. (CHGG) securities between May 5, 2020, and November 1, 2021. For more on the CHGG Lawsuit please contact us today.
According to the Chegg lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Chegg’s increase in subscribers, growth, and revenue had been a temporary effect of the COVID-19 pandemic that resulted in remote education for the vast majority of United States students and once the pandemic-related restrictions eased and students returned to campuses nationwide, Chegg’s extraordinary growth trends would end; (ii) Chegg’s subscriber and revenue growth were largely due to the facilitation of remote education cheating – an unstable business proposition – rather than the strength of its business model or the acumen of its senior executives and directors; and (iii) as a result, the Company’s current business metrics and financial prospects were not as strong as it had led the market to believe during the Class Period.
If you suffered a loss in Chegg you have until February 22, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an FFIE class action lawsuit has been filed on behalf of investors who purchased Faraday Future Intelligent Electric Inc. F/K/A Property Solutions Acquisition Corp.(FFIE) securities between January 28, 2021, and November 15, 2021. For more on the FFIE Lawsuit please contact us today.
According to the Faraday Future lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had assets in China frozen by courts, (2) a significant percentage of its deposits for future deliveries were attributable to a single undisclosed affiliate; (3) the Company’s cars were not as close to production as the Company claimed; (4) as a result of previously issued statements that were misleading and/or inaccurate, Faraday Future could not timely file its quarterly report; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Faraday Future you have until February 22, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a DM class action lawsuit has been filed on behalf of investors who purchased Desktop Metal, Inc. (DM) securities between March 15, 2021, and November 15, 2021. For more on the DM Lawsuit please contact us today.
According to the Desktop Metal lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint: (1) there were deficiencies in EnvisionTEC’s manufacturing and product compliance practices and procedures; (2) the foregoing deficiencies presented a material risk to the commercialization of EnvisionTEC’s products; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Desktop Metal you have until February 22, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an ARVL class action lawsuit has been filed on behalf of investors who purchased Arrival SA. (ARVL) securities between November 18, 2020, and November 19, 2021. For more on the ARVL Lawsuit please contact us today.
According to the Arrival lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company would record a substantially greater net loss and adjusted earnings before interest, taxes, depreciation, and amortization (“EBITDA”) loss in the third quarter of 2021 compared to the third quarter of 2020; (ii) the Company would experience far greater capital and operational expense to operate and deploy its micro-factories and manufacture EV vehicles than it had disclosed; (iii) the Company would not capitalize on or achieve profitability or provide meaningful revenue in the time periods disclosed; (iv) the Company would not achieve its disclosed production and sales volumes; (v) the Company would not meet the disclosed production rollout deadlines. Accordingly, the Company materially overstated its financial and operational position and/or prospects, and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Arrival you have until February 22, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a MARA class action lawsuit has been filed on behalf of investors who purchased Marathon Digital Holdings, Inc. f/k/a Marathon Patent Group, Inc. (MARA) securities between October 13, 2020, and November 15, 2021. For more on the MARA Lawsuit please contact us today.
According to the Marathon lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint: (i) the Beowulf Joint Venture, as it related to the Hardin Facility, implicated potential regulatory violations, including U.S. securities law violations; (ii) as a result, the Beowulf Joint Venture subjected Marathon to a heightened risk of regulatory scrutiny; (iii) the foregoing was reasonably likely to have a material negative impact on the Company’s business and commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Marathon you have until February 15, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a RETA class action lawsuit has been filed on behalf of investors who purchased Reata Pharmaceuticals, Inc. (RETA) securities between November 9, 2020, and December 8, 2021. For more on the RETA Lawsuit please contact us today.
According to the Reata lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration had raised concerns regarding the validity of the clinical study designed to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome; (2) as a result, there was a material risk that Reata’s New Drug Application would not be approved; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Reata you have until February 18, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an RDW class action lawsuit has been filed on behalf of investors who purchased Redwire Corporation f/k/a/ Genesis Park Acquisition Corp (RDW) securities between August 11, 2021, and November 14, 2021. For more on the RDW Lawsuit please contact us today.
According to the Redwire lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) there were accounting issues at one of Redwire’s subunits; (2) as a result, there were additional material weaknesses in Redwire’s internal control over financial reporting; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Redwire you have until February 15, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a BIDU class action lawsuit has been filed on behalf of investors who purchased Baidu, Inc. (BIDU) securities between March 22, 2021, and March 29, 2021. For more on the BIDU Lawsuit please contact us today.
According to the Baidu lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the filed complaint: Goldman Sachs Group Inc. and Morgan Stanley sold a large number of Baidu shares while in possession of material non-public information. The defendants knew that Archegos Capital Management would need to fully liquidate its position in Baidu based on margin call pressures. The defendants avoided billions in losses by selling the Company’s shares while in possession of this information. When the market learned the truth about Baidu, investors suffered damages.
If you suffered a loss in Baidu you have until February 14, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a HOOD class action lawsuit has been filed on behalf of investors who purchased Robinhood Markets, Inc.(HOOD) shares pursuant and/or traceable to the Company’s initial public offering (“IPO”) conducted in July 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. For more on the HOOD Lawsuit please contact us today.
According to the Robinhoodlawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the lawsuit, documents that the Company issued in connection with its IPO contained representations that were materially inaccurate, misleading, and/or incomplete because they failed to disclose that, at the time of the IPO, Robinhood’s revenue growth was experiencing a major reversal, with transaction-based revenues from cryptocurrency trading serving only as a short-term, transitory injection masking what was actually stagnating growth. In addition, the Company’s “significant investments” in enhancing the reliability and scalability of its platform were patently inadequate and/or defective, exposing Robinhood to worsening service-level disruptions and security breaches, particularly as the Company scaled its services to a larger user base.
If you suffered a loss in Robinhood you have until February 15, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a PSFE class action lawsuit has been filed on behalf of investors who purchased Paysafe Limited (PSFE) securities between December 7, 2020, and November 10, 2021. For more on the PSFE Lawsuit please contact us today.
According to the Paysafe lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Paysafe was being negatively impacted by gambling regulations in key European markets; (2) Paysafe was encountering performance challenges in its Digital Wallet segment; (3) new eCommerce customer agreements were being pushed back; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Paysafe you have until February 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that an SNBR class action lawsuit has been filed on behalf of investors who purchased Sleep Number Corporation (SNBR) securities between February 18, 2021, and July 20, 2021. For more on the SNBR Lawsuit please contact us today.
According to the Sleep Number lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) Sleep Number had suffered a severe disruption in its supply chain for foam as a result of Winter Storm Uri; (b) Sleep Number did not have in place the supply chain flexibility, redundancies and fail-safes, as had been represented to investors, sufficient to offset the foam supply disruption caused by Winter Storm Uri; (c) because foam was a necessary component for Sleep Number’s production of its primary mattress products, Sleep Number’s ability to timely fulfill customer orders had been materially impaired; (d) as a result of (a)-(c) above, Sleep Number was unable to meet surging customer demand for the Company’s products; and (e) as a result of (a)-(d) above, Sleep Number had been forced to delay mattress shipments to end consumers, pushing millions of dollars’ worth of sales into subsequent quarters and negatively impacting the Company’s financial results.
If you suffered a loss in Sleep Number you have until February 14, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP announces that a RAAS class action lawsuit has been filed on behalf of investors who purchased Cloopen Group Holding Limited (RAAS) (a)pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 2021 initial public offering; and/or (b)between February 9, 2021, and May 10, 2021, inclusive. For more on the RAAS Lawsuit please contact us today.
According to the Cloopen lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: an increasing number of its customers were refusing to pay, forcing the Company to record massive increases in its accounts receivables and allowance for doubtful accounts. The Registration Statement also failed to disclose that Cloopen was weighed down by massive liabilities related to the fair value of certain recently-granted warrants.
If you suffered a loss in Cloopen you have until February 8, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
